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CHAPTER 1: BACKGROUND AND SIGNIFICANCE
Aging
Aging is a multifactorial process that reflects all of the changes that emerge over the
progression of life [1]. Aging itself is not a disease [2]. However, with growth, development and
maturity comes increased vulnerability to disease and ultimately resulting in mortality [3]. In other
terms, aging, as defined by Fedarko is “the decline and deterioration of functional properties at the
cellular, tissue and organ level” [4]. Aging is associated with the alteration of several physiological
processes, such as loss of homeostasis and loss of functional capacity. In turn, individuals become
more susceptible to developing diseases [1]. Morbidities associated with aging include, but are not
limited to: cancer, neurodegenerative disorders, autoimmune disease, cardiovascular disease, and
type II diabetes mellitus [5]. Since these diseases are highly prevalent in the geriatric population,
targeting them individually limits the benefit that could be obtained. As a result, researchers are
working to target the aging process as a whole in order to delay the occurrence of age-related
diseases, in turn delaying aging.
Lifespan extending strategies
Over 60 years ago, McCay presented a major paradigm; he showed that it was possible to
extend the lifespan of laboratory rodents by simply adjusting their diet [6]. Caloric restriction,
which is a 40% restriction of diet without malnutrition, is the most extensively studied life
extending strategy to date [7]. Caloric restriction is shown to increase both health span and lifespan
in many species[2], but this increase is not universal among different strains of the same species.
Upon examination of body weight and longevity data, it was shown that the increase in lifespan of
certain genotypes due to caloric restriction, is directly related to the gain in body weight under the
Ad libitum feeding regimen [7]. In other terms, it may not necessarily be that caloric restriction is
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increasing lifespan. On the contrary, overfeeding may be causing the animals to become
overweight, and susceptible to early onset of disease and aging. It’s also been shown that weight
loss as a result of caloric restriction improved glucose tolerance. Also, caloric restriction increased
insulin sensitivity in middle aged healthy men and women [8]. Caloric restriction improved these
processes (glucose tolerance and insulin sensitivity), which are often found impaired in overweight
and obese individuals. The mechanism underlying the beneficial effect of caloric restriction has
not yet been determined, but it has been speculated that it’s affecting a major nutrient sensing
pathway, mTOR.
Over the past 20 years, methionine restriction arose as a promising dietary restriction
mimetic [9]. Methionine restriction is a 60-80% restriction in the essential amino acid in the diet.
It results in a comparable increase in lifespan as compared to caloric restriction but does not require
food restriction[10]. Animals fed methionine restricted diets are much smaller than control but
consume more food per body weight [11]. Similar to caloric restriction, methionine restriction
increases insulin sensitivity and improves lipid metabolism[10]. Though the mechanism by which
methionine restriction increases lifespan was shown to be through activation of autophagy [12]. A
human lifestyle consisting of a methionine restricted diet is not easily attainable since it would
require developing highly palatable methionine depleted proteins.
Ames dwarf mice surfaced as a valuable model to understand the aging process[13]. These
mice have a pituitary deficiency that renders them very small due to a significant reduction in
growth hormone, prolactin, and thyroid stimulating hormone. The Ames dwarf mice live
significantly longer than their normal siblings. These genetically modified dwarf mice have
significantly lower levels of insulin like growth factor-I. ILGF-1 is a mediator of growth hormone
action on growth and directly impacts mTOR.
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More recently, two major drugs have also been shown to increase lifespan by directly
targeting mTOR. Rapamycin, also known as Sirolumus, is a macrolide immunosuppressant drug
with anti-proliferative properties[14]. It was initially used as an anti-fungal agent. Rapamycin, a
direct inhibitor of the TOR kinase of mTORC1, extends lifespan in various animal models [5].
Rapamycin treatment in some studies results in impaired glucose homeostasis and insulin
resistance, which are associated with reduced lifespan [15, 16]. These findings present a paradox
of improved survival despite metabolic impairment. Fang et. Al explained this outcome by
showing that the duration of rapamycin treatment had a differential effect on metabolism in mice
[17].
Metformin, an oral anti-diabetic drug used as first line treatment of type II diabetes mellitus
[18], increases lifespan in animal models. Treatment with metformin has been shown to alleviate
several human aging-related disorders, such as cancer and non-alcoholic fatty liver disease [19].
Metformin mimics caloric restriction by increasing insulin sensitivity, glucose utilization, and fatty
acid oxidation. In mammals, metformin promotes lifespan through activation of a major metabolic
fuel gauge (AMPK)[20]. Activation of AMPK increases mitochondrial ROS production and
induces stress defense that results in increased longevity; a process known as mitohormesis [19].
Metformin mimics antifolate chemotherapeutic agents such as pemetrexed that directly inhibit
multiple folate-dependent targets in the one carbon metabolism, in turn leading to the activation
of AMPK and inhibition of mTOR [21].
mTOR
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that
regulates cell growth, autophagy, and proliferation by modulating protein synthesis and
homeostasis[22]. It is present in two multiprotein complex forms: mTORC1 and mTORC2.
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mTORC1 pathway integrates input from various upstream intracellular and extracellular signals
that include growth factors, stress, oxygen, energy status, and amino acid levels. The best
characterized process downstream of mTORC1 is protein synthesis, via phosphorylation of two
downstream target proteins: S6K1 and 4E-BP1[23].

Unlike mTORC1, much less is known about mTORC2. mTORC2 is not sensitive to
nutrients but it responds to growth factors in poorly defined mechanisms[23]. Whereas mTORC1
is activated via phosphorylation of AKT at the TH308 residue downstream of the PI3K signaling
pathway, mTORC2 phosphorylates and activates AKT at the SER473 residue; the site required for
maximal activation[24]. mTORC2 also activates PKCα along with other effectors and regulates
the cell’s shape by affecting the actin cytoskeleton[25].
Genetic Downregulation of mTOR
The mTOR signaling pathway is altered in many cancers [24]. Genetic down-regulation of
TOR signaling delays aging in evolutionary distant organisms from yeast to mammals[26]. Selman
et. Al showed that deletion of ribosomal S6 protein kinase 1 (S6K1), a target of mTORC1, extends
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median lifespan in female mice by 19%. It also induces a healthy mammalian lifespan by
improving insulin sensitivity, and increasing resistance to age-related pathologies, such as bone,
immune, and motor dysfunction [27]. In another study, genetic reduction of mTOR expression to
25% of wild type increased mammalian lifespan. They showed that these animals have reduced
both mTORC1 and mTORC2 activity, and exhibit a 20% increase in median survival [28].
Folic Acid
A major micro-nutrient that impacts this nutrient sensing (mTOR) pathway is folic acid.
Folic acid is an essential water soluble B-vitamin and a cofactor in one-carbon metabolism. It is
the synthetic form of the naturally occurring vitamin folate, and is used in supplements and food
fortification programs. It has been associated with the etiology of many chronic diseases such as
cardiovascular disease, neurological degeneration, and cancer [29].
Folate Metabolism
Folic acid enters through the diet and mediates one-carbon transfer. It is converted to
dihydrofolate, then reduced to tetrahydrofolate (THF). In a series of reactions that require
MTHFD, THF is then converted to N5, N10 methyleneTHF affecting purine and thymidine
synthesis. Folate, in the form of 5-methylTHF, is involved in the remethylation of homocysteine
to methionine, a precursor of S-adenosylmethionine (SAM). SAM is the primary methyl group
donor for most biological methylations including that of DNA. SAM is then converted into Sadenosylhomosysteine (SAH), a potent inhibitor of most SAM-dependent methyltransferases.
Homocysteine is also converted to cysteine and to the anti-oxidant glutathione via the
transsulfuration pathway.
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It had been speculated that inadequate folate may lead to uracil misincorporation and
deoxynucleotide imbalance, resulting in single strand breaks and DNA damage. Recent evidence
suggests that nuclear folate levels were resistant to folate depletion when total cellular folate levels
were reduced by more than 50% in the liver. Under folate deficiency (0 mg of Folic acid per Kg
diet), MTHFD localizes and becomes enriched in the nucleus to support thymidylate biosynthesis,
protecting the DNA by limiting uracil misincorporation. By localizing and enriching in the
nucleus, thymidylate biosynthesis is favored over remethylation of homocysteine to methionine
[30]. We speculate that the timing and duration of folate restriction result in epigenetic changes in
the DNA. Though further studies are required to confirm.
Folate Study
Our lab established an animal model to study the effect of folate in the diet. Data is lacking
on folate requirement for mice, and on mice plasma folate levels in the wild. Chow diet was not
chosen since the amount of folic acid in it is variable (2 mg-15mg), with an average of 8 mg of
folic acid per kg of diet. The diets that we used were a folate adequate (2 mg of FA/kg diet) or a
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folate depleted (0 mg FA/kg diet) AIN93G-purified isoenergetic diet. After 12 weeks on the
respective diets, plasma folate levels in our mice were assessed to confirm drop of folate in the
animals fed a folate depleted diet. There was a 90% decrease in plasma folate in these mice (figure
1.1). We also looked at the effect of a folate depleted diet on plasma folate levels at various time
points. Plasma folate levels decreased by the 3rd day of the animals being on a folate depleted diet
(figure 1.2). Since no further decrease was observed after the first week on the diet, and the animals
did not show any signs of anemia, we termed this condition folate restriction rather than folate
deficiency.
Folate Restriction and extension in lifespan
Preliminary data from our lab shows that folate restriction extends median lifespan in our
C57BL/6 mouse model. At 850 days of life, 86% of the animals that were on a folate restricted
diet were still alive as compared to 60% of the animals that were on a folate adequate diet.
Folate Restriction and colon carcinogenesis
Our lab investigated the effect of folate restriction on colon carcinogenesis in β-pol
haploinsufficient mice [31]. A β-pol haploinsufficient background has limited base excision repair,
thus exposure to a carcinogen results in DNA damage that will not be efficiently repaired. As
shown in figure 1.3, there was no ACF (Aberrant crypts per foci) in the colon of control mice fed
a folate adequate or a folate depleted diet; indicating that β-pol haploinsufficiency by itself, and βpol haploinsufficiency in combination with folate restriction do not cause ACF formation.
We treated our mice with DMH (Dimethylhydrazine), a methylating agent that causes
colon and liver cancer. Upon examining the data, there was a significant increase in the number of
ACF in the colons of folate restricted wild type and folate adequate β-pol haploinsufficient
animals. Surprisingly, folate restriction reduced ACF numbers to levels similar to the folate
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adequate wild type. Rather than exacerbating the problem, β-pol haploinsufficiency in
combination with folate restriction provided a protective effect. This observation went against our
expectation. We were interested then to see if this protection is limited to the β-pol
haploinsufficient genetic background.
Long term vs. short term Folate restriction
Our lab became interested in investigating the duration that these animals can survive
without an essential vitamin. After leaving them for 16 months on a folate depleted diet, the
animals were not showing any signs of anemia, and they looked healthier than their folate adequate
counterparts. Furthermore, exposing the mice to a carcinogen after having acclimated to a
prolonged folate restricted diet resulted in very few ACF. In this small trial, we saw that long term
folate restriction did not result in the adverse side effects mentioned in literature. The results also
contradicted what we saw in short term folate restriction in our previous study.
In order to confirm these results, we designed a study to look at whether the duration of
folate restriction before exposure to a carcinogen has a differential effect on ACF in mice. The
animals were fed either a FA (2 mg FA/kg diet) diet, FR (0 mg FA/kg diet), or FA/FR (7 weeks
on FA diet then 1 week on FR diet) for a total of 8 weeks. Animals were randomly chosen, exposed
to DMH, and later sacrificed.
Upon examining serum folate levels, we saw a significant decrease in serum folate in both
short term (FA/FR) and long term (FR) folate restricted groups (figure 1.4). There was a 90%
decrease in serum folate levels, similar to what we have seen before. When we examined the ACF
data (figure 1.5), we saw that the duration of folate restriction had a differential effect on ACF in
our mouse model. Placing the animals on a folate restricted diet a week before DMH treatment
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(FA/FR) resulted in a significant increase in ACF as compared to FA. Interestingly, animals on
long term folate restriction (FR) had fewer ACF in the colon as compared to FA.
When we compared ACF to serum folate levels, we saw that eventhough folate levels were
significantly lower in both folate restricted groups, in one group (FA/FR) it was unfavorable while
in another (FR) it was protective; where we saw a decrease in adverse side effects. These results
are similar to what we saw in our previous study. Introducing two stressors concurrently without
giving the animals time to adapt is disadvantageous. On the other hand, giving the animals time to
adapt to folate restriction was protective, where we saw significantly less ACF. (Figure 1.5)
In this study, we first investigate the effect of folate restriction on the mTOR signaling
pathway, by examining upstream regulators and downstream targets of mTOR. Data suggests that
folate restriction downregulates the mTOR signaling pathway mainly via activation of AMPK.
Then we compare the effect of 3 well documented life extending strategies (Rapamycin, crowded
litter, caloric restriction, and their control) on the mTOR signaling pathway. Data shows that not
all of the strategies downregulate mTOR. Furthermore, the impact seen on upstream regulators of
mTOR is differential.
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Figure 1.1: The effect of folate in the diet on plasma folate levels in C57BL/6 mice. The animals
were fed either a folate adequate (FA) or folate depleted (FD) AIN93G-purified isoenergetic diet
(Dyets, Inc., Lehigh Valley, PA) as previously described[32]. The FA group received a folate
adequate diet containing 2 mg of folic acid/kg diet. The FD group received a folate-deficient diet
containing 0 mg of folic acid/kg diet. The animals remained on their respective diets for 12 weeks
after which they were sacrificed. Plasma was collected and folate levels were analyzed using the
lactobacillus casei microbiological assay[33]. * Significant differences at P < 0.05.
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Figure 1.1: The effect of folate in the diet on plasma folate levels in C57BL/6 mice.

12

Figure 1.2: The effect of folate depletion in the diet on plasma folate levels at various time points.
C57BL/6 mice were fed either a folate adequate (FA) or folate depleted (FD) AIN93G-purified
isoenergetic diet (Dyets, Inc., Lehigh Valley, PA) as previously described[32]. The FA group
received a folate adequate diet containing 2 mg of folic acid/kg diet. The FD group received a
folate-deficient diet containing 0 mg of folic acid/kg diet. The animals remained on their respective
diets for the duration of the study. Blood was drawn from the capillary of the eye at various time
points, and folate levels were analyzed using the lactobacillus casei microbiological assay [33].
Different letters indicate significant differences at P < 0.05.
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Figure 1.2: The effect of folate depletion in the diet on plasma folate levels at various time points.
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Figure 1.3: The effect of folate restriction on colon carcinogenesis in β-pol haploinsufficient mice.
WT and β-pol+/− C57BL/6 mice were fed either a folate-adequate (2 mg FA/kg diet) or a folatedeficient (0 mg FA/kg diet) diet. After 1 week on the respective diets, animals were randomly
chosen and were injected with 30 mg/kg body weight of DMH for 6 weeks. Six weeks after the
final injection, animals were sacrificed by CO2 asphyxiation. The abdominal cavity was opened
and the colon was excised, rinsed with cold phosphate-buffered saline, cut longitudinally, and
fixed flat overnight in 10% neutral buffered formalin. On the next day, the colonic crypts were
stained with 2 g/liter of methylene blue in phosphate-buffered saline for 5 min. The number of
ACF was determined by light microscopy at ×10 magnification in a blinded manner. Different
letters indicate significant differences at P < 0.05.
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Figure 1.3: The effect of folate restriction on colon carcinogenesis in β-pol haploinsufficient
mice.
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Figure 1.4: The effect of long term and short term folate restriction with/out antibiotic
incorporation in the diet on serum folate levels. C57BL/6 mice were fed either a folate adequate
(FA), long term folate depleted (FR), or short term folate depleted (FA/FR) AIN93G-purified
isoenergetic diet (Dyets, Inc., Lehigh Valley, PA) as previously described [32]. 1% succinyl
sulfathiazole was added to some of the diets (+AB). The FA group received a folate adequate diet
containing 2 mg of folic acid/kg diet. The FR (Long term folate restriction) group received a folatedeficient diet containing 0 mg of folic acid/kg diet. The FA/FR (Short term folate restriction) group
received a folate adequate diet for 7 weeks, then switched to a folate deficient diet for one week
before animals were randomly chosen and injected with DMH once a week for 6 weeks at 30
mg/kg body weight. The animals remained on their respective diets until they were sacrificed at
21 weeks. Upon sacrifice, serum was collected and folate levels were analyzed using the
lactobacillus casei microbiological assay [33]. Different letters indicate significant differences at
P < 0.05.
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Figure 1.4: The effect of long term and short term folate restriction with/out antibiotic
incorporation in the diet on serum folate levels.
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Figure 1.5: The effect of long term and short term folate restriction in the diet on ACF. C57BL/6
mice were fed either a folate adequate (FA), long term folate depleted (FR), or short term folate
depleted (FA/FR) AIN93G-purified isoenergetic diet (Dyets, Inc., Lehigh Valley, PA) as
previously described [32]. 1% succinyl sulfathiazole was added to some of the diets (+AB). The
FA group received a folate adequate diet containing 2 mg of folic acid/kg diet. The FR (Long term
folate restriction) group received a folate-deficient diet containing 0 mg of folic acid/kg diet. The
FA/FR (Short term folate restriction) group received a folate adequate diet for 7 weeks, then
switched to a folate deficient diet for one week before animals were randomly chosen and injected
with DMH once a week for 6 weeks at 30 mg/kg body weight. The animals remained on their
respective diets until they were sacrificed at 21 weeks. After sacrifice, the colon was excised,
rinsed with cold phosphate-buffered saline, cut longitudinally, and fixed flat overnight in 10%
neutral buffered formalin. On the next day, the colonic crypts were stained with 2 g/liter of
methylene blue in phosphate-buffered saline for 5 min. The number of ACF was determined by
light microscopy at ×10 magnification in a blinded manner. Different letters indicate significant
differences at P < 0.05.
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Figure 1.5: The effect of long term and short term folate restriction in the diet on ACF.
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CHAPTER 2: FOLATE RESTRICTION
Introduction
Aging is a multifactorial process associated with alterations in several physiological
functions [1]. It increases susceptibility to disease due to loss of functional capacity and loss of
homeostasis [2]. Some of the associated diseases include cancer, neurodegenerative disorders,
autoimmune disease, cardiovascular disease, and type II diabetes mellitus [5]. Since these diseases
are highly prevalent in the geriatric population, targeting the aging process as a whole may provide
a better way to delay incidences of many age related diseases [5, 34]. Some of the interventions
that have been known to delay aging include: caloric restriction [6], methionine restriction [9],
genetic alterations such as Ames dwarf mice [13], rapamycin [35], and metformin [19]. These
interventions affect and inhibit a major nutrient sensing pathway, mammalian target of rapamycin
(mTOR) [35-39]. The mTOR signaling pathway is altered in many cancers [26] , and downregulation of TOR signaling delays aging in a number of organisms, ranging from yeast to
mammals [27, 28, 38, 40-42].
A major micronutrient that has been associated with the etiology of many of these age
related diseases is folate. Folate is an essential water soluble B-vitamin, naturally present in green
vegetables, legumes, and citrus fruits. The synthetic form, folic acid, is used in supplements and
food fortification programs (1998 FDA mandate) [43]. Folate plays a critical role in one carbon
metabolism. It is involved in purine and pyrimidine biosynthesis, amino acid metabolism,
regeneration of S-Adenosyl methionine, and glutathione production [44]. Folate is involved in
normal development & maintenance of cellular functions, genomic integrity, and regulation of
gene expression [45].
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Folate deficiency has been associated with many ailments including: megaloblastic
anemia, cardiovascular disease, neurodegenerative diseases, and cancer [46-51]. Epidemiological
and laboratory rodent based studies show an association between folate deficiency and colorectal,
prostate, and breast cancers [52-56]. Although the exact mechanism behind folate deficiency
induced carcinogenesis is largely unknown, low folate has been shown to cause genomic
instability, DNA uracil misincorporation, alterations in DNA methylation pattern, DNA strand
breakage, and chromosomal aberrations [46, 57-60]. Folate deficiency acts synergistically with
damaging agents, reducing DNA damage threshold, and increasing mutation frequency [61-64]. A
possible mechanism behind folate deficiency induced genomic instability and cancer development,
may be impaired DNA repair pathways [65, 66]. To directly test how folate deficiency induces
colon cancer, we analyzed the impact of folate deficiency on the onset and progression of cancer
in a polymerase  haploinsufficient (-pol+/-) mouse model. -pol is a rate limiting enzyme in the
BER pathway, required for the repair of oxidative DNA damage and uracil misincorporation.
Our lab showed that a folate depleted diet in combination with -pol haploinsufficiency
reduced incidences of preniosplastic lesions [31]. BrdU and TUNEL assays revealed a decrease in
the proliferative capacity, and an increase in apoptosis in the colon of FR animals [31]. Others
have also shown that reduced dietary folate decreased tumor incidence in various mouse cancer
models [67-69]. Kadaveru and colleagues showed that folate deficiency protected against intestinal
tumor development in the colon of APCMIN/+ mice [68]. MacFarlane and colleagues showed that
folate deficiency was negatively correlated with inflammatory bowel disease, a risk factor for
developing colon cancer [69]. Bistulfi and colleagues reported that folate deficiency blocked
prostate cancer progression in the TRAMP animal model, generally characterized with aggressive
tumors [67]. These findings provide insight about the anti-cancer effect of folate restriction.
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Inhibition of folate synthesis, extended lifespan in C. elegans [70]. Down regulation of Sadenosyl methionine synthase, a critical enzyme in the one carbon folate metabolism, also
extended lifespan in C. elegans [71]. Metformin, an emerging gerosuppressant, impaired one
carbon metabolism similar to antifolate drugs in human cancer cells [21]. It’s well established that
folic acid cofactors are involved in De novo purine synthesis necessary for AMP biosynthesis [7274]. Stenesen and colleagues showed that a mutation in the AMP biosynthesis pathway increased
healthy lifespan [75]. Folate restriction may result in alterations in the De novo purine biosynthesis
pathway, impacting aging and cancer. We present folate restriction as a possible nutritional
intervention to extend lifespan and improve healthspan, and the objective of this study is to
characterize the mechanism.
Experimental Procedures
Animals- All the experiments were performed in male C57BL/6 specific pathogen–free young
wildtype mice in accordance with NIH guidelines for the use and care of laboratory animals. The
Animal protocol was approved by the Wayne State University Animal Investigation Committee.
The animals were fed the standard mouse chow and water ad libitum and were maintained on a
12-hr light/dark cycle.
Diets and Carcinogen treatment- Experiment 1: At 6 weeks of age, mice were randomly assigned
to two dietary groups and fed AIN93G-purified isoenergetic diets (Dyets, Inc.,Lehigh Valley,PA)
[32]. Diets were stored at -20°C. The control group (FA) received a folate adequate diet (2mg
FA/kg diet). The experimental group (FR) received a folate deficient diet (0 mg folic acid/kg diet).
Diets were supplemented with 1% succinyl sulfathiazole. The animals were monitored for signs
of toxicity and remained on their respective diets for 12 weeks. Mice were anesthetized in a CO 2
chamber and the abdominal cavity was opened up for excising the colon and harvesting the liver
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tissue. The harvested liver was flash frozen and stored in liquid nitrogen. Experiment 2: At 4
months of age, mice were randomly assigned to three dietary groups and fed AIN93G-purified
isoenergetic diets (Dyets, Inc.,Lehigh Valley,PA) [32]. Diets were stored at -20°C. The control
group (FA) received a folate adequate diet (2mg FA/kg diet for 8 weeks). The experimental groups:
(FR) received a folate deficient diet (0 mg folic acid/kg diet for 8 weeks) and (FA/FR) received
(2mg FA/kg diet for 7 weeks then 0 mg folic acid/kg diet for 1 week for a total of 8 weeks). Diets
were supplemented with 1% succinyl sulfathiazole. After 8 weeks on the respective diets, mice
were treated IP with 1, 2-dimethylhydrazine HCl (DMH, 30 mg/kg body weight) in 10 mmol/litre
of NaHCO3 (Fisher Scientific) once a week for 6 weeks [31]. The animals were monitored for
signs of toxicity and remained on their respective diets for a total of 21 weeks. Mice were
anesthetized in a CO2 chamber and the abdominal cavity was opened up for excising the colon and
harvesting the liver tissue. The harvested liver was flash frozen and stored in liquid nitrogen
Folate Assay: Serum was collected upon sacrifice. Folate was measured using the Lactobacillus
casei microbiological assay of folic acid derivatives as described by Horne et. Al [33]. Briefly,
growth response of lactobacillus casei to folate availability was measured at OD 600 nm. A
standard curve was used to calculate folate concentrations. Folate levels are expressed as percent
folate. The assay was conducted courtesy of Dr. Cabelof’s lab.
Amino Acid Levels: Plasma was collected upon sacrifice and sent to MSU and UC-Davis for HPLC
analysis. Amino Acid pool and plasma amino acid are expressed as ratio of FR/FA.
Aberrant crypt foci (ACF) analysis- The excised colons were rinsed with cold phosphate-buffered
saline, cut longitudinally, and fixed flat overnight in 10% neutral buffered formalin as described
previously [31]. The fixed colons were stained with 2g/liter of methylene blue in phosphate-
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buffered saline for 5 mins. The number of ACF and aberrant crypts per foci were determined by
light microscopy at 10X magnification in a blinded manner as described previously [31].
Isolation of Crude Nuclear extract- Nuclear extracts were isolated using a transfactor extraction
kit (Clontech, Mountain View, CA) as previously described [76]. Briefly, a hypotonic buffer is
used to lyse the cell allowing for the removal of cytosolic fractions, followed by a hypertonic
buffer which helps in the extraction of nuclear proteins. All solutions were made fresh and all
samples and tubes were maintained on ice. Low molecular weight contaminants were removed
from extracts by dialysis using Slide-A-LyzerR mini-dialysis units (Pierce Biotechnology,
Rockford, IL) with a molecular weight cut off of 3.5 KD for 3 hours at 4°C. The dialysis buffer
has 20mM Tris-HCl, pH 8.0, 100mM NaS2O5, 0.1mM PMSF, and 1mg/ml Pepstatin A. Dialyzed
extracts were aliquoted and stored at -80°C for subsequent analysis. Protein concentrations were
determined using to Bradford protein assay kit I (Bio-Rad, Hercules, CA).
Isolation of Whole cell extract- Whole cell extracts were isolated using hypotonic and hypertonic
salt solutions from transfactor extraction kit (Clontech, Mountain View, CA). Briefly, 100mg of
liver tissue was homogenized with the hypotonic salt solution to lyse the cell and further treated
with the hypertonic salt solution to release the nuclear contents without any fractionations. The
whole cell extract thus obtained was used for various assays.
Western Blot Analysis- Protein expression analysis was performed using western blot technique as
previously described [76]. 100 g nuclear protein was used to run the SDS-PAGE. Upon
completion of SDS-PAGE, the region containing the proteins of interest was excised and prepared
for western blot analysis while the remaining portion of the gel was stained with Gel Code Blue
Stain Reagent (Pierce Biotechnology, Rockford, IL) to ensure equal protein loading. Manufacturer
recommended dilutions of anti-sera developed against p-AMPK (Abcam), t-AMPK (Millipore),
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p-AKT (Cell Signaling), t-AKT (Cell Signaling), REDD1 (Abcam), p53 (Abcam), PARP (Cell
Signaling), IPMK (Abcam), p-S6K1 (Cell Signaling), t-S6K1 (Cell Signaling), p-4EBP1 (Cell
Signaling), t-S6K1 (Cell Signaling), PEPCK (Santa Cruz) and G6PASE (Santa Cruz) were used
to detect proteins of interest followed by incubation with HRP-conjugated secondary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA). The bands were visualized and quantified using a
Molecular Imager System (Bio-Rad, Hercules, CA) after incubation in SuperSignal West Pico
Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL). Data are expressed as the
integrated density value (I.D.V.) of the band normalized to -actin (Sigma Aldrich) or ratio of
phosphorylated form of protein to total normalized to -actin.
Gene expression profiling- The mRNA expression levels of SIRT1 and Gadd45g were quantified
using a real-time PCR. Total RNA was extracted from liver tissue using RNeasy extraction kit
(Qiagen, Valencia, CA). First strand cDNA was synthesized from 1g RNA using random primers
and purified using QIAquick PCR purification Kit (Qiagen, Valencia, CA). Expression of SIRT1
was quantified using real time PCR with specific primers for the gene (FP: 5’AACTTCACAGCATCTTCAAT3’ and RP 5’-TGACACTGTGGCAGATTGTT3’). Expression
of Gadd45g was quantified using real time PCR with specific primers for the gene (FP: 5’AGTTCCGGAAAGCACAGCCAGGATG-3’

and

RP:

5’-

GCCAGCACGCAAAAGGTCACATTGT-3’). The gene transcript was normalized to RPLO with
specific primers for the gene (FP: 5’-AATTTCAATGGTGCCTCTGG-3’ and RP: 5’GATTCGGGATATGCTGTTGG-3’). External standards for all genes were prepared by
subcloning the amplicons, synthesized using the specific primers into PGEM-T easy vector.
Caspase Assay- Caspase-3 activity was measured using Enzchek Caspase-3 Assay Kit No.1
(Molecular probes, Eugene, OR) as described previously [76]. Briefly, Liver tissues were
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homogenized, and cytosolic extracts were isolated using Transfactor Extraction Kit (Clonetech,
Mountain View, CA). The extracts (250 mg protein) were incubated for 2hr at room temperature
in the working solution (25mM PIPES, pH 7.4, 5mM EDTA and 2.25% CHAPS) containing
synthetic caspase-3 substrate, Z-DEVD-AMC. Caspase mediated proteolytic cleavage of the
substrate yields a bright blue-fluorescent product. An additional control assay was performed using
reversible aldehyde inhibitor Ac-DEVD-CHO to confirm that the fluorescence observed in the
sample assay was due to caspase activity. The fluorescence was measured using a fluorescence
microplate reader (Genios plus, Tecan) at excitation: 342nm, emission: 441nm. The caspase
activity was determined using an AMC (7-amino-4-methylcoumarin) standard curve (0-100mM),
and reported as fluorescence per mg of protein.
ATP Assay: Total ATP was extracted from 10 mg of liver using Abcam’s ATP Assay kit. This is
a calorimetric assay that utilizes the phosphorylation of glycerol to generate product that is easily
quantified at OD 570 nm. Total amount (cellular and mitochondrial) of active ATP is detected.
ATP levels are expressed as (nmoles/ml).
NAD/NADH Assay: Total NAD (NAD and NADH) was extracted from 20 mg of liver using
Abcam’s NAD/NADH Assay kit. This is a calorimetric assay that detects intracellular nucleotides
at OD 570 nm. Total NAD is extracted and detected. Then NAD+ is decomposed to detect NADH.
The values are used to calculate for NAD+. NAD+ levels are expressed as (uM). The ratio of NAD+
to NADH is also calculated.
Statistical Analysis- Statistical significance between means was determined using t-test and
analysis of variance followed by post tukey test wherever appropriate. P-values less than 0.05
were considered statistically significant.
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Results
Analysis of folate status in the diet on plasma folate levels in C57Bl/6 mice:
We established an animal model to study the effect of dietary folate. Data is lacking on
folate requirement for mice, and on mice plasma folate levels in the wild. Chow diet was not
chosen since the amount of folic acid in it is variable (2 mg-15 mg), with an average of 8 mg of
folic acid per kg of diet. The diets that were used were a folate adequate diet (2 mg of folic acid
per kg of diet) or a folate depleted diet (0 mg of folic acid per kg of diet). Both diets were
supplemented with 1% succinyl sulfathiazole, an antibiotic known to alter flora in the colon
limiting the number of bacteria that can generate folate. We randomly assigned 8 C57BL/6 mice
at 6 weeks of age into two groups. One group was fed a folate adequate diet, while the other group
was fed a folate depleted diet. The animals remained on their respective diets for 12 weeks and
then sacrificed. Plasma was collected, colon was excised, and tissues were harvested and flash
frozen in liquid nitrogen for further analysis. Similar to what we have shown before [31], the
amount of food consumed and body weight did not significantly differ between groups (Data not
shown).
Plasma folate levels were assessed at various time points throughout the study. There was
60% reduction in plasma folate by the 3rd day on the folate depleted diet, and 90% reduction within
the first and second weeks Figure 2.1. The 90% reduction in plasma folate was maintained for the
duration of the 12 week study Figure 2.2. Since no further decrease was observed after the first
week on the diet, and the animals did not show any signs of anemia, this condition was termed
folate restriction rather than folate deficiency.
Analysis of the development of preneoplastic lesions during folate restriction in C57Bl/6 mice:
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Low folate status has been associated with the development and progression of various
types of cancer, specifically colorectal cancer [52-54]. However, recent studies show that low
folate may be protective against spontaneous [77], and chemically induced cancer [78, 79].
Inconsistencies in these studies may be due to differences in experimental design, dosages, timing
and duration of folate deficiency. In the first experiment, we investigated the effect of low folate
status on the development of spontaneous preneoplastic lesions in the colon of C57BL/6 mice. We
looked at aberrant crypt foci (ACF), which are clusters of preneoplastic legions, and are the earliest
changes in the colon that may lead to cancer [80-82]. Aberrant crypts develop as single crypts, and
grow over time in a process known as crypt fission. They appear as a foci with multiple aberrant
crypts, and are homogenous in their genetic make-up. Animals were placed on a folate adequate
(FA) or folate restricted (FR) diet for 12 weeks, after which they were sacrificed for analysis. The
numbers of ACF and aberrant crypts per foci were determined using light microscopy. As shown
in Figure 2.3, the colons from FA and FR groups appeared morphologically normal, with no signs
of aberrant crypts. Folate restriction by itself proves to be a low penetrance event. It does not
independently give rise to spontaneous preneoplastic lesions.
In the second experiment, we investigated the effect of low folate status on the development
of chemically induced preneoplastic lesions in the colon of C57BL/6 mice. 1,2-dimethylhydrazine
(DMH), a potent colon and liver carcinogen, was used to induce ACF. The DMH-mouse model of
colon carcinogenesis is extensively studied [83-87]. Cancer is induced in a manner histologically
similar to human colon cancer [88-90]. DMH is a known alkylating agent that is activated in the
liver [91, 92]. Upon activation, DMH produces metabolic intermediates that are transported to the
colon via bile and blood [93, 94]. The colon is also capable of converting DMH into mutagenic
products without involving the liver[95]. We randomly assigned C57Bl/6 mice into 3 groups.
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Animals were fed a FA ( 2 mg FA/kg diet) diet, FA/FR ( 7 weeks on FA diet then 1 week on FR
diet), or FR ( 0 mg FA/kg diet) for a total of 8 weeks; after which we began their carcinogen
treatment. All three groups were injected with 30 mg/kg body weight of DMH, once a week for 6
weeks. Seven weeks after the final DMH injection, the mice were sacrificed and the colons were
scored for aberrant crypt foci. As shown in Figure 2.4, the FR animals which were acclimated to
folate depletion for 8 weeks prior to DMH treatment, showed significantly less ACF than FA. On
the contrary, the FA/FR animals which were treated with DMH one week after folate depletion,
showed significantly higher number of ACF as compared to both FA and FR. Also, ACF did not
correlate with plasma folate levels (Data not shown). Eventhough folate levels were significantly
lower in both folate restricted groups, there was a differential effect on ACF. There was
significantly more ACF in the short term folate restricted group (FA/FR), but significantly less
ACF in the long term folate restricted group (FR). Giving the animals time to adapt to folate
restriction before introducing a carcinogen was protective, in terms of seeing significantly less
ACF (Figure 2.4).
Aberrant crypt foci, once formed, can regress with time. Persistence of these aberrant
crypts, and occurrence of foci with multiple aberrant crypts, correlates with tumor aggressiveness.
A foci with more than two aberrant crypts can potentially develop and progress into an adenoma
and adenocarcinoma. Upon evaluation of crypt multiplicity, the acclimated FR animals displayed
reduced crypt multiplicity (1.49) when compared to FA (1.87) and FA/FR (2.33). Long term
acclimation to folate restriction reduces susceptibility to environmental insults, and can potentially
reduce development of colon cancer. Our study shows that an acclimation period on a folate
depleted diet is essential to detect the beneficial effect of FR, and can explain the inconsistencies
surrounding the pro-carcinogenic impact of folate deficiency.
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Analysis of one-carbon cycle, amino acid metabolism and energy metabolism during folate
restriction:
Folate is an essential water soluble B-vitamin that plays a vital role in one carbon
metabolism (Figure 2.5). In the first segment of the pathway, dietary folate is converted to
dihydrofolate, then reduced to tetrahydrofolate (THF). THF is then converted to N5, N10
methyleneTHF affecting purine and thymidine synthesis. The reduced folates act as cofactors for
the biosynthesis of amino acids such as glycine. The second segment of the one carbon cycle is
the trans-methylation pathway. Folate, in the form of 5-methylTHF, is involved in the
remethylation of homocysteine to methionine, an essential amino acid and a precursor of the
universal methyl donor S-adenosylmethionine (SAM). The third segment of the folate cycle
consists of the trans-sulfuration pathway. This results in the conversion of homocysteine into
cystathionine, then to cysteine and then to the antioxidant glutathione. Therefore, folate plays a
central role in nucleic acid biosynthesis, DNA methylation and epigenetics, amino acid
metabolism, and redox regulation (Figure 2.5).
We analyzed the effect of a 12 week FR regimen on plasma amino acid pools, nucleotide
biosynthesis, and energy metabolism. As shown in Table 2.1, there was an overall reduction in
plasma amino acid levels in FR. Of importance were methionine levels, which were reduced by
~60% in FR as compared to FA. This revealed a physiological methionine restriction, created by
the folate depleted diet. Despite the decrease in methionine, homocysteine levels were also reduced
in FR. This observation was contrary to common belief that folate deficiency increases
homocysteine levels [96]. In addition, branched chain amino acids (BCAA), shown to have
regulatory effects on cellular proliferation and growth, such as valine, leucine and isoleucine [97],
were also significantly reduced in FR (Table 2.1). However, FR significantly increased -alanine
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levels (~40%), suggesting uracil catabolism. Uracil pools are generally catabolized to -alanine
by the sequential action of the enzymes dihydropyrimidine dehydrogenase, dihydropyrimidinase
and -alanine synthase [98]. Folate restriction, although may increase uracil accumulation, it also
increases uracil breakdown possibly to protect the DNA by limiting uracil misincorporation. Field
et. Al showed that a long term folate deficient diet did not affect the uracil content in liver genomic
DNA [30].
Tryptophan levels were also lower in FR as compared to FA (Table 2.1). Tryptophan is the
precursor of the water soluble vitamin Niacin. Niacin is the generic name for nicotinic acid and
nicotinamide, the precursors for coenzyme Nicotinamide adenine dinucleotide (NAD) [99]. NAD
cycles between the oxidized (NAD+) and reduced (NADH) forms, partaking a central role in
cellular metabolism and energy production [100]. To determine the impact of FR on energy
metabolism, we analyzed NAD+ levels, and NAD+/NADH ratio in the liver. Using a calorimetric
assay, we detected intracellular nucleotides (NAD total and NADH). There was a significant
increase in NAD+ levels (~ 85%) (Figure 2.6) and in NAD+/NADH ratio (~78 %) (Figure 2.7) in
FR as compared to FA. In addition, SIRT1, also known as NAD-dependent deacetylase sirtuin-1,
was significantly upregulated in FR (Figure 2.8). To directly test the impact of FR on energy
metabolism, we determined total ATP levels in the liver using a colorimetric assay. Total ATP
levels were significantly reduced (~60%) in FR as compared to FA (Figure 2.9). Our data suggests
that folate restriction impacts and modifies the one carbon metabolism, potentially modulating
downstream nutrient sensing pathways.
Analysis of the nutrient sensing pathway - mTOR in the liver of C57Bl/6 mice during folate
restriction:
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Our lab has previously shown that folate deficiency in combination with -pol
haploinsufficiency confers protection against the development of chemically induced
preneoplastic lesions [31]. BrdU and TUNEL assays confirmed a decrease in the proliferative
capacity, and an increase in apoptosis in the colon of FR mice [31]. Microarray analysis of the
folate deficient -pol+/- animals showed a significant reduction in the expression of DNA repair
genes, and significant upregulation in the expression of the pro-apoptotic genes [31]. In line with
our previous data, our acclimated FR animals displayed reduced proliferation (~30%) when
compared to FA. Colons were immunostained for Ki-67, an indicator of proliferation in the colon
(data not shown). Microarray analysis of the colon showed a significant reduction in the expression
of mTOR in FR as compared to FA (Table 2.2). To further elucidate the molecular mechanism
behind the anti-proliferative effect of folate restriction, we looked at the signaling pathway central
to proliferation and cell growth, the mTOR pathway.
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that regulates
cell growth, autophagy and proliferation [23]. It integrates signals from upstream factors, and is
modulates between growth and starvation [101]. mTOR dysregulation is implicated in aging and
in many age-related diseases [24]. mTOR exists in two multiprotein complexes: mTORC1 and
mTORC2.

mTORC1 pathway integrates input from various upstream intracellular and

extracellular signals that include: growth factors (ILGF), stress, hypoxia, energy status
(AMP/ATP, NAD+ /NADH), purine metabolism, and amino acid levels [101]. The best
characterized process downstream of mTORC1 is protein synthesis, via phosphorylation of two
downstream target proteins: S6K1 and 4E-BP1[23]. mTORC1 phosphorylates and activates
4EBP1, relieving inhibition off of protein synthesis [102, 103]. On the other hand, S6K1
phosphorylation and activation by mTORC1, promotes ribosome biogenesis and protein synthesis
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[103, 104]. Therefore, mTORC1 is a crucial regulator of protein synthesis, cellular proliferation
and metabolism [103-105].
mTORC2 is not sensitive to nutrients but responds to growth factors by poorly defined
mechanisms[23]. Whereas mTORC1 is activated via phosphorylation of AKT at the TH308
residue downstream of the PI3K signaling pathway, mTORC2 phosphorylates and activates AKT
at the SER473 residue; the site required for maximal activation[24]. mTORC2 also activates PKCα
along with other effectors and regulates the cell’s shape by affecting the actin cytoskeleton[25].
mTORC1 is regulated through intermediary effectors that relay intracellular and
extracellular upstream signals; such as IPMK, REDD1, AMPK, and AKT. IPMK mediates the
activation of mTORC1 in response to amino acids. This regulation is independent of its catalytic
function, instead it binds to mTOR and raptor maintaining the mTOR-raptor association [106].
IPMK also physiologically binds AMPK, and inhibits its activity in a glucose dependent manner
[107], in turn activating mTORC1. Folate restriction reduced the protein levels of IPMK, but there
was no significant difference (Figure 2.10). REDD1 levels increased following exposure to
hypoxia or DNA damage, leading to activation of TSC1/TSC2 complex, and inhibition of mTOR
signaling. There was a significant decrease in REDD1 expression in FR as compared to FA (Figure
2.11). This indicates that the downregulation of mTORC1 may not necessarily be mediated by
IPMK or REDD1.
Folate restriction significantly increases phosphorylation of AMPK (pAMPK) (Figure
2.12), an inhibitor of mTORC1. AMPK is a metabolic fuel gauge that detects changes in
intracellular AMP/ATP ratio [108]. AMPK is activated in response to nutrient depletion, and it
acts to maintain energy stores by switching on pathways that produce ATP, and switching off
pathways that consume ATP [108]. AMPK directly inhibits mTORC1, and neutralizes PI3K
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activation of mTORC1. AMPK enhances SIRT1 activity (Figure 2.8) by increasing cellular levels
of NAD+ (Figure 2.6), both of which were seen upregulated in our FR animals. Accumulation of
AICAR, an intermediate formed during De novo purine biosynthesis [109], and a potent activator
of AMPK [110], can occur during folate restriction. Furthermore, Low ATP levels activate AMPK
and inhibit hepatic gluconeogenesis in an insulin independent manner [111]. This effect of hepatic
AMPK inhibition of gluconeogenesis, overrides the inductive signal elicited through glucagon.
Folate restriction resulted in reduced expression of PEPCK (rate limiting enzyme in
gluconeogenesis) (Figure 2.13), but there was increased expression of G6PASE (Figure 2.14),
possibly as a feedback mechanism due to decreased glucose and gluconeogenesis. Interestingly,
FR increased phosphorylation of AKT S473, a target of insulin-like growth factors (Figure 2.15).
AKT S473 phosphorylation is mTORC2 dependent.
These factors converge on downregulation of mTORC1 but not mTORC2 during folate
restriction. mTORC1 dependent phosphorylation of 4EBP1 (Figure 2.16) and S6K1 (Figure 2.17)
were reduced in FR as compared to FA. FR downregulates mTORC1, reducing protein synthesis
and cellular proliferation. Folate restriction specifically reduces mTORC1 expression, while it
induces mTORC2, possibly as a compensatory mechanism to promote survival [5]. Lamming et
al. demonstrated that mTORC2 expression is required for maintaining insulin sensitivity, and was
important for the insulin-mediated suppression of hepatic gluconeogenesis [5]. Folate restriction
alters the one-carbon metabolism, and the downstream mTOR nutrient sensing network, possibly
explaining the anti-proliferative and anti-cancer effects observed.
Analysis of apoptosis in the liver of C57Bl/6 mice during folate restriction:
Apoptosis acts as a protective mechanism during stress, and helps to eliminate damaged
DNA and eventually damaged cells [112]. It is an essential process for maintaining homeostasis
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and survival in multi-cellular organisms [113]. To characterize the effect of folate restriction on
cell cycle arrest and apoptosis, we analyzed four markers of apoptosis: Gadd45 (growth arrest
and DNA damage-inducible gene ), p53, caspase 3, and parp-1 cleavage. Using real-time PCR
we analyzed the mRNA expression of gadd45a genotoxic stress-inducible gene associated with
cell cycle arrest and apoptosis. We saw decreased expression of Gadd45(~38%) in FR as
compared to FA (Figure 2.18). Since Gadd45is a p53 responsive gene, and p53 is a wellestablished regulator of cell cycle arrest and apoptosis [114, 115], we next evaluated the
stabilization of p53 protein. P53 stabilization is dependent on S6K1 phosphorylation and inhibition
of the E3 ubiquitin ligase MDM2 [116]. Since we saw reduced p-S6K1 in FR (Figure 2.17), we
presumed that MDM2 may be free to inhibit p53. As expected, we saw decreased nuclear p53
protein in FR as compared to FA (Figure 2.19). We also determined the activity of caspase-3.
Upon activation, caspases initiate cell death and drive the process of apoptosis [117]. Caspase-3
activity was significantly reduced (~26%) in FR (Figure 2.20). We further determined the cleavage
of parp-1, an early indicator of apoptosis. PARP-1 cleavage by caspases is a hallmark of apoptosis
[118]. We saw decreased PARP-1 cleavage in FR as compared to FA (Figure 2.21). Folate
restriction reduced apoptotic activity in our animals. This reduction in apoptosis may be an
adaptation to modulate between reduced damage and reduce proliferation, possibly slowing down
the aging process.
Analysis of folate restriction as a potential anti-aging dietary intervention:
Aging is a multifactorial process that increases vulnerability to disease and eventually leads
to mortality. Interventions that delay aging include: nutritional manipulations (caloric restriction
[6] and methionine restriction [9]), genetic models (Ames dwarf mice [13]), and drug treatments
(rapamycin [35] and metformin [19]). These interventions either impact cellular energy stores
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(NAD+/NADH ratio and ATP production), or directly modulate the nutrient sensing pathway
mTOR. Rapamycin, an immunosuppressant drug, is a potent inhibitor of mTOR signaling [14]. It
extends lifespan of yeast, flies and mice by directly inhibiting the TOR kinase of mTORC1 [40,
42, 119]. Caloric restriction, the most established life extending strategy, also inhibits the mTOR
pathway [36]. Metformin, an oral antidiabetic drug, extends lifespan in C. elegans by activating
AMPK [39]. Increased activation of AMPK, a sensor of AMP levels and an inhibitor of mTORC1,
also increases lifespan in flies [120]. Human breast cancer cells treated with Metformin showed
impaired one-carbon metabolism similar to the effect of anti-folate chemotherapeutic drugs [21].
Treatment with metformin resulted in accumulation of a folate variant essential for de novo purine
and pyrimidine synthesis [21].
Interestingly, metformin suppressed angiogenesis and proliferation of DMH induced colon
cancer in diabetic and non-diabetic mice [121]. We had previously shown that a folate deficient
diet in combination with -pol haploinsufficiency reduced incidences of DMH induced
preneoplastic lesions [31]. We have also shown that acclimated folate restriction modulates the
onset and progression of cancer (Figure 2.4). Since cancer is one of the most important age related
diseases, and since FR modulates one-carbon metabolism, energy metabolism, and mTOR, we
hypothesized that folate restriction can potentially extend lifespan. We maintained 4 week old mice
on a FR diet to study the impact of the diet on their lifespan. Plasma folate levels were monitored
periodically and showed 90% reduction in folate, similar to what we have shown before (Figure
2.2). FR mice did not show any signs of anemia, or development of spontaneous cancers. Their
food consumption and body weight did not significantly differ from their folate adequate
counterparts. At 32 months of age, FR animals appeared physiologically younger than their folate
fed counterparts. Based on our ongoing survival study, FR modulates survival independent of
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caloric restriction. Our aging colony shows an 86% survival rate for FR mice as compared to 60%
survival for FA at 850 days of life (Figure 2.22). In this study, we have identified a direct link
between the folate cycle and the nutrient sensing mTOR pathway, both of which converge on target
genes impacting aging and cancer.
Discussion
Folate deficiency has been associated with many age-related diseases. Birth defects,
specifically neural tube defects (NTD’s), have also been linked to dietary folate deficiency. NTD
is a complex disorder that is caused by various genetic, nutritional, and environmental factors.
NTD is congenital malformation with genetic etiology that includes trisomy 13, trisomy 18,
specific chromosome rearrangements, and Meckel Gruber syndrome [122]. Apart from genetic
susceptibility, pregnant mothers who are obese, have poorly controlled diabetes, take anti-seizure
medications, or take anti-folate drugs, are more pre-disposed to having babies with NTD’s [123].
Over the years, research showed that adequate folic acid intake, before and during pregnancy can
greatly reduce the prevalence of NTD’s [124]. These findings led to the 1998 FDA mandate to
fortify all staple food items with folic acid. Although there has been roughly a 19% drop in NTD’s
since the fortification, it is not clear whether this drop is actually due to fortification, increased
awareness, improved nutrition or increased prenatal diagnosis[125].
Quinlivan and Gregory show that there is a linear relationship between folate intake and
plasma folate levels [126]. However, not many studies have been conducted to directly check the
adverse effects of elevated folic acid intake [127]. Emerging studies show an increased risk of
many types of cancer since the fortification, specifically colorectal and prostate cancer [128] .
Apart from cancer, increased folate levels have been shown to mask Vitamin B-12 deficiency, and
aggravate neurologic impairment [129]. Furthermore, excess folic acid (supplements or fortified
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foods) can suppress Natural Killer cells that are vital for normal immune functioning in
postmenopausal women[130]. There was a significant increase in the unmetabolized folic acid
levels in the fasting plasma of 78% of subjects. Unmetabolized or oxidized forms of folic acid are
not naturally present is food sources. Dihydrofolate reductase (DHFR) is the rate limiting enzyme
that is responsible for physiologically converting folic acid to the reduced form of folate. In
humans, increased folic acid intake can lead to accumulation of unmeatbolized folic acid in the
plasma, due to the slow activity of DHFR in the liver[131]. This warrants the need for further
studies to characterize the toxicity of unmetabolized folic acid in the plasma, and its potential long
term effect on immune function and health[130].
Earlier studies showing the association of folate hypo-insufficiency with various cancers
are inconsistent. These studies vary in the intervention implemented, and in the dosage and timing
of the dietary folate regimens [58]. While many epidemiological and animal studies show a strong
correlation between low folate and cancer [52, 54], other studies show the association of folate
supplementation and cancer [78, 132]. Therefore, the effect of folate on the manifestation of many
diseases, specifically cancer, remains inconclusive. Folic acid supplementation promotes the
progression of aberrant crypt foci into colorectal cancer in AOM treated rats[132]. Folic acid
supplementation also has tumor-promoting effect on pre-existing preneoplastic lesions [133].
NHANES data show that 32-38% of individuals aged over 60 years have high serum folate
concentrations [134, 135], and 25-50% of people develop asymptomatic colorectal adenomas by
50 years of age [136]. These figures indicate that folic acid supplementation is potentially a risk
factor for cancer development and progression[132]. Furthermore, rats kept on a folate depleted
diet for 4 weeks before AOM treatment showed reduced incidences of intestinal tumors, and
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numbers of malignant tumors [137]. It’s proposed that the decrease in tumor numbers may be due
to folate’s role in cell multiplication or proliferation.
Our lab had previously demonstrated that a combination of folate deficiency and -pol
haploinsufficiency reduced the development of preneoplastic lesions in the colon [31]. This
combination also reduced crypt multiplicity in our model. We also observed that an acclimation
period on the FR diet is an important factor to detect the beneficial impact of FR. Wild-type
C57Bl/6 mice were fed a long term folate-depleted diet ( 0 mg FA/kg diet for 8 weeks), a folate
adequate diet ( 2mg FA/kg diet for 8 weeks) or a short term folate depleted diet ( 2 mg FA/kg diet
for 7 weeks, then 0 mg FA/kg diet for 1 week) prior to the start of DMH treatment. Long term
folate depletion before exposure to a carcinogen resulted in significantly less ACF. Interestingly,
we find that methionine restriction (MR), a regimen shown to extend lifespan [138], requires a
period of adaptation to exhibit its anti-cancer effect, similar to FR (Manuscript in preparation).
Our data imply that long-term FR results in a folate restricted microenvironment that is protective
against spontaneous and chemically induced cancer.
To explain the protective effect of FR, we analyzed its impact on amino acid pools, energy
metabolism, and nucleotide biosynthesis in mice. These factors are important for cellular survival
and proliferation, as they impact a major nutrient sensing pathway, mTOR. We demonstrated that
a 12 week FR regimen reduced plasma amino acid levels, specifically methionine, isoleucine, and
leucine. Despite the decrease in methionine, FR did not increase levels of homocysteine. FR
increased -alanine levels, suggesting that uracil is being catabolized. This finding is supported by
Field et. Al, indicating that a long term FD diet did not affect the uracil content in liver genomic
DNA [30]. We also demonstrated that FR significantly decreased total ATP levels in the liver. FR
increased NAD+ levels and NAD+/NADH ratio. An increase in NAD+ has been associated with
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elevation of SIRT1 expression [139]. We saw a significant increase in SIRT1 expression in FR.
FR also increased phosphorylation of AMPK, a metabolic fuel gauge that senses changes in
AMP/ATP ratio, and modulates mTORC1. FR downregulates mTORC1 as observed by the
decreased activation of two downstream targets: S6K1 and 4E-BP.
Furthermore, FR significantly increased AKT S473 phosphorylation. This site is
phosphorylated by mTORC2. FR increased phosphorylation of AKT at the S473 residue possibly as
a compensatory mechanism to maintain insulin sensitivity [5, 140]. Interestingly, we also observed a

significant decrease in the expression of the gluconeogenesis enzyme PEPCK.
mTOR signaling is also impacted by REDD1 expression in response to hypoxia and DNA
damage [141]. REDD1 is a transcriptional target gene of p53 [142]. In response to DNA damage,
REDD1 expression is upregulated, inhibiting mTORC1. We show that FR decreased expression
of REDD1. This suggests that the effect seen on the downregulation of mTORC1 in our model,
may not be mediated through REDD1. Downstream of mTOR, phosphorylation of S6K1,
phosphorylates and inactivates MDM2, in turn stabilizing p53 in the nucleus [116]. FR reduced
S6K1 phosphorylation, so we expected MDM2 inhibition on p53 translocation to the nucleus. We
observed reduced nuclear p53, reduced expression of the p53 responsive cell cycle arrest gene
Gadd45g, and consequently decreased caspases 3 activity. FR imposes a low level of stress that is
insufficient to promote apoptosis, but creates a balance between reduced proliferation and
apoptosis. We suggest that keeping apoptosis down is beneficial in the absence of DNA damage.
Elevated apoptosis, while anti-cancerous, accelerates aging.
mTOR is a major nutrient sensing pathway that impacts aging, and many age-related
diseases. Inhibition of mTOR extends life-span in many laboratory models including yeast, worms,
flies and rodents [35, 119, 143, 144]. Wu et. Al demonstrated that downregulation of mTOR to
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25% of wild type increased median lifespan by 20% in mice, and slowed down tissue-specific
aging [28]. We propose that folate restriction, a nutritional intervention that impacts the mTOR
pathway, potentially extends lifespan. Our FR animals showed significantly improved survival
rate when compared to FA at 1250 days of life. Upon gross analysis at sacrifice, aged FR animals
did not show signs of macroscopic tumors. FR significantly extends the life-span of long-lived
flies fed media containing 0.3M folate versus 1M folate (data not shown). Observations made in
C. elegans showed that reduction in the folate pathway increased life-span [70, 71]. We show that
FR extends life span of our experimental mouse model, without developing spontaneous tumors.
The pro-longevity and anti-cancer effects of folate restriction appear to be due to modulation of
the folate pathway, purine biosynthesis, energy metabolism, and converging on the nutrient
sensing pathway, mTOR.
Two major life extending strategies, caloric restriction and rapamycin have been shown to
inhibit mTOR [35-37]. Folate restriction, also an inhibitor of mTOR, is a novel anti-aging/anticancer nutritional intervention. It combines the beneficial effects of rapamycin and caloric
restriction, while avoiding their drawbacks. Unlike caloric restriction, FR is an attainable
nutritional intervention that would be more feasible to implement within the human population.
FR impacts the nutrient sensing pathway as a whole, avoiding the resistance seen in rapamycin, a
direct inhibitor of mTORC1. Moreover, chronic rapamycin treatment inhibits both mTORC1 and
mTORC2 [15]. This in turn compromises insulin sensitivity and impairs glucose tolerance. Unlike
rapamycin, FR enhances mTORC2 activity, possibly maintaining insulin sensitivity.
Folate restriction infers protection against the onset and progression of cancer in mice, and
extends their median lifespan. The innovative nature of our findings, is that they contradict the
current understanding of the role of folate status on the etiology of cancer. These results may

42

represent a new paradigm in our current understanding of folate supplementation and the
ramifications on the health and cancer risk of various subsets of the population.
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Figure 2.1: The effect of folate depletion in the diet on plasma folate levels at various time points.
C57BL/6 mice were fed either a folate adequate (FA) or folate depleted (FD) AIN93G-purified
isoenergetic diet (Dyets, Inc., Lehigh Valley, PA) as previously described [32]. The FA group
received a folate adequate diet containing 2 mg of folic acid/kg diet. The FD group received a
folate-deficient diet containing 0 mg of folic acid/kg diet. The animals remained on their respective
diets for the duration of the study. Blood was drawn from the capillary of the eye at various time
points, and folate levels were analyzed using the lactobacillus casei microbiological assay [33].
Values represent an average [S.E.M] for data obtained from 4 mice in each group and are
representative of separate identical experiments. Different letters indicate significant differences
at P < 0.05.
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Figure 2.1: The effect of folate depletion in the diet on plasma folate levels at various time points.
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Figure 2.2: The effect of folate in the diet on plasma folate levels in C57BL/6 mice. The animals
were fed either a folate adequate (FA) or folate depleted (FD) AIN93G-purified isoenergetic diet
(Dyets, Inc., Lehigh Valley, PA) as previously described[32]. The FA group received a folate
adequate diet containing 2 mg of folic acid/kg diet. The FD group received a folate-deficient diet
containing 0 mg of folic acid/kg diet. The animals remained on their respective diets for 12 weeks
after which they were sacrificed. Plasma was collected and folate levels were analyzed using the
lactobacillus casei microbiological assay[33].Values represent an average [S.E.M] for data
obtained from 4 mice in each group and are representative of separate identical experiments. *
Significant differences at P < 0.05.
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Figure 2.2: The effect of folate in the diet on plasma folate levels in C57BL/6 mice.
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Figure 2.3: The effect of folate restriction on development of spontaneous preneoplastic lesions.
The animals were fed either a folate adequate (FA) or folate depleted (FD) AIN93G-purified
isoenergetic diet (Dyets, Inc., Lehigh Valley, PA) as previously described [32]. The FA group
received a folate adequate diet containing 2 mg of folic acid/kg diet. The FD group received a
folate-deficient diet containing 0 mg of folic acid/kg diet. The animals remained on their respective
diets for 12 weeks after which they were sacrificed. After sacrifice, the colon was excised, rinsed
with cold phosphate-buffered saline, cut longitudinally, and fixed flat overnight in 10% neutral
buffered formalin. On the next day, the colonic crypts were stained with 2 g/liter of methylene
blue in phosphate-buffered saline for 5 min. The number of ACF was determined by light
microscopy at ×10 magnification in a blinded manner. A representative colon image of a mouse
exposed to folate restriction.
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Figure 2.4: The effect of long term and short term folate restriction on ACF. C57BL/6 mice were
fed either a folate adequate (FA), long term folate depleted (FR), or short term folate depleted
(FA/FR) AIN93G-purified isoenergetic diet (Dyets, Inc., Lehigh Valley, PA) as previously
described[32]. 1% succinyl sulfathiazole was added to some of the diets (+AB). The FA group
received a folate adequate diet containing 2 mg of folic acid/kg diet. The FR (Long term folate
restriction) group received a folate-deficient diet containing 0 mg of folic acid/kg diet. The FA/FR
(Short term folate restriction) group received a folate adequate diet for 7 weeks, then switched to
a folate deficient diet for one week before animals were randomly chosen and injected with DMH
once a week for 6 weeks at 30 mg/kg body weight. The animals remained on their respective diets
until they were sacrificed at 21 weeks. After sacrifice, the colon was excised, rinsed with cold
phosphate-buffered saline, cut longitudinally, and fixed flat overnight in 10% neutral buffered
formalin. On the next day, the colonic crypts were stained with 2 g/liter of methylene blue in
phosphate-buffered saline for 5 min. The number of ACF was determined by light microscopy at
×10 magnification in a blinded manner. Values represent an average [S.E.M] for data obtained
from 14 mice in each group and are representative of separate identical experiments. Different
letters indicate significant differences at P < 0.05.
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Figure 2.4: The effect of long term and short term folate restriction on ACF.
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Figure 2.5: Folate Cycle “One Carborn Metabolism”.
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Figure 2.6: Effect of folate restriction on NAD+ levels. Total NAD (NAD+ and NADH) was
extracted from the liver of C57BL/6 mice fed either FA or FR diet, using Abcam’s NAD/NADH
Assay kit. Intracellular nucleotides are detected using a plate reader at OD 570 nm. Total NAD is
extracted and detected. Then NAD+ is decomposed to detect NADH. The values are then used to
calculate for NAD+. NAD+ levels are expressed as (uM). Values represent an average [S.E.M] for
data obtained from 4 mice in each group and are representative of separate identical experiments.
* Significant differences at P < 0.05. FA: Folate adequate; FR: Folate restricted.
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Figure 2.6: Effect of folate restriction on NAD+ levels.
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Figure 2.7: Effect of folate restriction on NAD+/NADH ratio. Total NAD (NAD+ and NADH) was
extracted from the liver of C57BL/6 mice fed either FA or FR diet, using Abcam’s NAD/NADH
Assay kit. Intracellular nucleotides are detected using a plate reader at OD 570 nm. First, total
NAD is extracted and detected. Then NAD+ is decomposed to detect NADH. The values are then
used to calculate for NAD+. NAD+/NADH ratio calculated. Values represent an average [S.E.M]
for data obtained from 4 mice in each group and are representative of separate identical
experiments. * Significant differences at P < 0.05. FA: Folate adequate; FR: Folate restricted.
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Figure 2.7: Effect of folate restriction on NAD+/NADH ratio.
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Figure 2.8: Effect of folate restriction on SIRT1 mRNA expression. SIRT1 mRNA levels in the
liver tissue of C57BL/6 mice fed FA or FR diets were quantified using real-time PCR. Values
represent an average [S.E.M] for data obtained from 4 mice in each group and are representative
of separate identical experiments. * Significant differences at P < 0.05. FA: Folate adequate; FR:
Folate Restricted.
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Figure 2.9: Effect of folate restriction on ATP levels. Total ATP was extracted from the liver of
C57BL/6 mice fed FA or FR diets using Abcam’s ATP Assay kit. Active ATP was measured using
a plate reader at OD 570 nm. ATP levels are expressed as nmoles/ml. Values represent an average
[S.E.M] for data obtained from 4 mice in each group and are representative of separate identical
experiments. * Significant differences at P < 0.05. FA: Folate adequate; FR: Folate restricted.
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Figure 2.9: Effect of folate restriction on ATP levels.
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Figure 2.10: Effect of folate restriction on expression of IPMK protein. The level of IPMK protein
in 100 ug of liver whole cell extract from C57BL/6 mice fed FA or FR diets was determined by
western blot analysis. The level of IPMK was normalized based on the amount of protein loaded.
The I.D.V (integrated density value) corresponding to the level of IPMK protein as quantified by
the BioRad Molecular Imager® System, normalized to β-actin. Values represent an average
[S.E.M] for data obtained from 4 mice in each group and are representative of separate identical
experiments. * Significant differences at P < 0.05. FA: Folate adequate; FR: Folate Restricted.
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Figure 2.10: Effect of folate restriction on expression of IPMK protein
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Figure 2.11: Effect of folate restriction on expression of REDD1 protein. The level of REDD1
protein in 100 ug of liver whole cell extract from C57BL/6 mice fed FA or FR diets was determined
by western blot analysis. The level of REDD1 was normalized based on the amount of protein
loaded. The I.D.V (integrated density value) corresponding to the level of REDD1 protein as
quantified by the BioRad Molecular Imager® System, normalized to β-actin. Values represent an
average [S.E.M] for data obtained from 4 mice in each group and are representative of separate
identical experiments. * Significant differences at P < 0.05. FA: Folate adequate; FR: Folate
Restricted.
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Figure 2.11: Effect of folate restriction on expression of REDD1 protein.
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Figure 2.12: Effect of folate restriction on AMPK phosphorylation. The level of AMPK protein in
100 ug of liver whole cell extract from C57BL/6 mice fed FA or FR diets was determined by
western blot analysis. The level of the phosphorylated form of AMPK was determined first. The
membrane was then stripped and tested for Total AMPK. The I.D.V (integrated density value)
corresponding to the level of AMPK protein (phosphorylated and total) was quantified by the
BioRad Molecular Imager® System. Phosphorylated AMPK was normalized to total and
expressed as p-AMPK protein expression ratio. Values represent an average [S.E.M] for data
obtained from 4 mice in each group and are representative of separate identical experiments. *
Significant differences at P < 0.05. FA: Folate adequate; FR: Folate Restricted.
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Figure 2.12: Effect of folate restriction on AMPK phosphorylation.
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Figure 2.13: Effect of folate restriction on gluconeogenesis enzyme PEPCK. The levels of PEPCK
protein in 100 ug of liver whole cell extract from C57BL/6 mice fed FA or FR diets were
determined by western blot analysis. The level of PEPCK was normalized based on the amount of
protein loaded. The I.D.V (integrated density value) corresponding to the level of PEPCK protein
as quantified by the BioRad Molecular Imager® System, normalized to β-actin. Values represent
an average [S.E.M] for data obtained from 4 mice in each group and are representative of separate
identical experiments. * Significant differences at P < 0.05. FA: Folate adequate; FR: Folate
Restricted.

65

Figure 2.13: Effect of folate restriction on gluconeogenesis enzyme PEPCK.
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Figure 2.14: Effect of folate restriction on gluconeogenesis enzyme G6PASE. The levels of
G6PASE protein in 100 ug of liver whole cell extract from C57BL/6 mice fed FA or FR diets were
determined by western blot analysis. The level of G6PASE was normalized based on the amount
of protein loaded. The I.D.V (integrated density value) corresponding to the level of G6PASE
protein as quantified by the BioRad Molecular Imager® System, normalized to β-actin. Values
represent an average [S.E.M] for data obtained from 4 mice in each group and are representative
of separate identical experiments. * Significant differences at P < 0.05. FA: Folate adequate; FR:
Folate Restricted.
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Figure 2.14: Effect of folate restriction on gluconeogenesis enzyme G6PASE
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Figure 2.15: Effect of folate restriction on AKT SER473 phosphorylation. The level of AKT protein
in 100 ug of liver whole cell extract from C57BL/6 mice fed FA or FR diets was determined by
western blot analysis. The level of the phosphorylated form of AKT at SER473 residue was
determined first. The membrane was then stripped and tested for Total AKT. The I.D.V (integrated
density value) corresponding to the level of AKT protein (phosphorylated and total) was quantified
by the BioRad Molecular Imager® System. P-AKT (ser473) was normalized to total AKT and
expressed as p-AKT ser473 protein expression ratio. Values represent an average [S.E.M] for data
obtained from 4 mice in each group and are representative of separate identical experiments. *
Significant differences at P < 0.05. FA: Folate adequate; FR: Folate Restricted.
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Figure 2.15: Effect of folate restriction on AKT SER473 phosphorylation.

60 KDa

70

Figure 2.16: Effect of folate restriction on 4EBP-1 phosphorylation. The level of 4EBP-1 protein
in 100 ug of liver whole cell extract from C57BL/6 mice fed FA or FR diets was determined by
western blot analysis. The level of the phosphorylated form of 4EBP-1 was determined first. The
membrane was then stripped and tested for Total 4EBP-1. The I.D.V (integrated density value)
corresponding to the level of 4EBP-1 protein (phosphorylated and total) was quantified by the
BioRad Molecular Imager® System. Phosphorylated 4EBP-1 was normalized to total and
expressed as p-4EBP-1 protein expression ratio. Values represent an average [S.E.M] for data
obtained from 4 mice in each group and are representative of separate identical experiments. *
Significant differences at P < 0.05. FA: Folate adequate; FR: Folate Restricted.
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Figure 2.16: Effect of folate restriction on 4EBP-1 phosphorylation.
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Figure 2.17: Effect of folate restriction on S6K1 phosphorylation. The level of S6K1 protein in
100 ug of liver whole cell extract from C57BL/6 mice fed FA or FR diets was determined by
western blot analysis. The level of the phosphorylated form of S6K1 was determined first. The
membrane was then stripped and tested for Total S6K1. The I.D.V (integrated density value)
corresponding to the level of S6K1 protein (phosphorylated and total) was quantified by the
BioRad Molecular Imager® System. Phosphorylated S6K1 was normalized to total and expressed
as p-S6K1 protein expression ratio. Values represent an average [S.E.M] for data obtained from 4
mice in each group and are representative of separate identical experiments. * Significant
differences at P < 0.05. FA: Folate adequate; FR: Folate Restricted.
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Figure 2.17: Effect of folate restriction on S6K1 phosphorylation.
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Figure 2.18: Effect of folate restriction on Gadd45g mRNA expression. Gadd45g mRNA levels in
the liver tissue of C57BL/6 mice fed FA or FR diets were quantified using real-time PCR.
Normalized to RPLO. Values represent an average [S.E.M] for data obtained from 4 mice in each
group and are representative of separate identical experiments. *Significant differences at P < 0.05.
FA: Folate adequate; FR: Folate Restricted.
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Figure 2.19: Effect of folate restriction on p53 nuclear localization. The level p53 protein in 100
ug of liver nuclear extracts from C57BL/6 mice fed FA or FR diets was determined by western
blot analysis. The level of p53 was normalized based on the amount of protein loaded. The I.D.V
(integrated density value) corresponding to the level of nuclear p53 protein was quantified by the
BioRad Molecular Imager® System, normalized to β-actin. Values represent an average [S.E.M]
for data obtained from 3 mice in each group and are representative of separate identical
experiments. * Significant differences at P < 0.05. FA: Folate adequate; FR: Folate Restricted.
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Figure 2.19: Effect of folate restriction on p53 nuclear localization.
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Figure 2.20: Effect of folate restriction on Caspase-3 activity. Cytosolic extracts were isolated
using 250 mg liver. Extracts were incubated at room for 2 hours in a working solution containing
synthetic caspase-3 substrate, Z-DEVD-AMC. Caspase mediated proteolytic cleavage of the
substrate yields a bright blue-fluorescent product. An additional control assay was performed using
reversible aldehyde inhibitor Ac-DEVD-CHO to confirm that the fluorescence observed in the
sample assay was due to caspase activity. The fluorescence was measured using a fluorescence
microplate reader (Genios plus, Tecan) at excitation: 342nm, emission: 441nm. The caspase
activity was determined using an AMC (7-amino-4-methylcoumarin) standard curve (0-100mM),
and reported as fluorescence per mg of protein. Values represent an average [S.E.M] for data
obtained from 4 mice in each group and are representative of separate identical experiments. *
Significant differences at P < 0.05. FA: Folate adequate; FR: Folate Restricted.

78

Figure 2.20: Effect of folate restriction on Caspase-3 activity.
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Figure 2.21: Effect of folate restriction on PARP-1 cleavage. The level of PARP-1 protein in 100
ug of liver whole cell extract from C57BL/6 mice fed FA or FR diets was determined by western
blot analysis. The level of PARP-1 was normalized based on the amount of protein loaded. The
I.D.V (integrated density value) corresponding to the cleavage of PARP-1 (cleaved/total) protein
as quantified by the BioRad Molecular Imager® System, normalized to β-actin. Values represent
an average [S.E.M] for data obtained from 3 mice in each group and are representative of separate
identical experiments. * Significant differences at P < 0.05. FA: Folate adequate; FR: Folate
Restricted.
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Figure 2.22: Effect of folate restriction on survival in C57BL/6 mice. The animals were fed either
a folate adequate or a folate depleted AIN93G-purified isoenergetic diet (Dyets, Inc., Lehigh
Valley, PA) as previously described [32]. The FA group received a folate adequate diet containing
2 mg of folic acid/kg diet. The FR group received a folate-deficient diet containing 0 mg of folic
acid/kg diet. The animals remained on their respective diets and survival was periodically
monitored until 33 months of age. FA: Folate adequate; FR: Folate Restricted.
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Table 2.1: Effect of folate restriction on plasma amino acid. Plasma was collected from C57BL/6
mice fed (FA) folate adequate diet ( 2 mg folic acid/kg diet) and (FR) folate restricted diet ( 0 mg
folic acid/kg diet) upon sacrifice. Data obtained from 4 mice in each group. Samples were sent to
MSU and UC-Davis for HPLC analysis. Amino aicd levels are expressed as ratio of FR to FA.
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Table 2.1: Effect of folate restriction on plasma amino acid.
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Table 2.2: Effect of folate restriction on mTOR pathway genes. Total RNA was isolated from the
colon mucosa of folate adequate and folate restricted mice using the RNeasy Mini Kit (Qiagen,
Valencia, CA) per manufacturer's protocol. RNA samples were quantified with NanoDrop ND1000 (NanoDrop Technologies, Inc, Wilmington, DE) and 260/280 ratio in the range of 2.0-2.2
was defined as acceptable. A quality check of the total RNA was performed using an Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA). Microarray expression profiling was
conducted by Microarray & Bioinformatics Facility Core at Wayne State University (Institute of
Environmental Health Sciences, Detroit, MI) according to the manufacturer’s protocol. Data
obtained from 4 mice in each group. Significant differences at P < 0.01. FR as compared to FA.
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CHAPTER 3: RAPAMYCIN, CROWDED LITTER AND CALORIC RESTRICTION
Introduction
Aging and age related diseases have been a major focus for researchers in various fields.
Aging is defined as “the decline and deterioration of functional properties at the cellular, tissue,
and organ level” [4]. The loss of homeostasis and loss of functional capacity associated with aging
increase susceptibility to developing many age related diseases [1]. Some of the associated
diseases include: cancer, neurodegenerative disorders, autoimmune disease, cardiovascular
disease and type II diabetes mellitus [5]. The high occurrence of these diseases in the geriatric
population limits the benefit obtained from targeting them individually [34]. Researchers have
been aiming to target the aging process as a whole in order to delay occurrence of age related
diseases, and in turn delaying aging.
The first documented life extending strategy was over 60 years ago. McCay demonstrated
that it was possible to extend lifespan of rodents by modifying their diet [6]. Since this discovery,
various nutritional interventions, genetic manipulations, and drug treatments were also shown to
delay aging [6, 9, 13, 19, 26-28, 35]. By delaying aging, these manipulations could potentially
have a protective effect on human health as a whole, which far exceeds the effect seen on individual
age related diseases. Since the published data on the beneficial effect of dietary interventions on
age related diseases were sporadic, they were not considered reliable or reproducible by the
scientific community [145]. This led the National Institute on Aging (NIA) to develop an
interventions testing program (ITP) to evaluate candidate agents known to delay aging or age
related diseases [145].
ITP approved different agents to be tested every year. Some of the compounds were tested
because they showed promising results in worms, flies or small scale rodent studies [145]. Others
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were chosen due to their impact on biochemical and physiological processes that are involved in
regulating aging [145]. ITP used genetically heterogeneous mice that were produced by a
standardized four way cross (UM-HET3) [146]. The use of heterogeneous mice would avoid
missing a true positive effect of an agent that may fail to work in a specific genotype [145]. It
would also reduce the chance of overemphasizing an agent that may work only in a specific
genotype [145]. Other key features of the program include: replication at three test sites (the
Jackson Laboratory, University of Michigan, and University of Texas), and a study design size
with more than 80% power to detect a 10% increase or decrease in median lifespan [145].
The emphasis of this research will be on a cohort study from the University of Michigan
that included three life extending strategies: Rapamycin, Caloric Restriction and Crowded Litter.
Rapamycin, also known as Sirolumus, is a macrolide immunosuppressant drug with antiproliferative properties [14]. Rapamycin inhibits the TOR kinase of mTORC1 and extends lifespan
in various animal models including: yeast, flies and mice [5]. Rapamycin extended lifespan of
heterogeneous male and female mice even when started late in life [42]. Caloric restriction, a welldocumented strategy in adults, also slows down aging and extends lifespan of rodents [6, 147149]. However, detrimental effects were seen in the offspring when exposed to undernutrition
during the gestation and/or lactation period [150, 151]. Recent evidence now suggests that preweaning food restriction increases lifespan in mice [152]. Crowded litter, a 50% increase in litter
size and a transient food restriction period during the first 20 days of life, extended mean and
maximal lifespan in mice [152]. The purpose of this study is to characterize the possible
mechanism behind the extension of lifespan seen in these three life extending strategies.
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Experimental Procedures
Animals- Genetically heterogeneous UM-HET3 mice were produced by crossing CByB6F1/J
female mice with C3D2F1/J male mice at the University of Michigan (UM). Details of breeding
have been explained in detail by Miller and coworkers [145, 153]. All experiments were performed
in male pathogen–free young mice from this heterogeneous background in accordance with NIH
guidelines for the use and care of laboratory animals.
Samples & Interventions- Liver samples from 32 UM-HET3 male mice were snap frozen in liquid
nitrogen upon sacrifice at 9 months of age from the University of Michigan. Group 1: control mice
were fed a chow diet (Purina 5LG6) from the time they were weaned until sacrifice (CON). Group
2: mice were fed encapsulated rapamycin (14 mg/kg food) incorporated into chow diet (Purina
5LG6) (RAPA) starting at 6 weeks of age. Group 3: mice from a crowded litter. The size of the
litter was increased to 12 pups per nursing mother. After 20 days, pups were weaned onto a normal
chow diet (Purina 5LG6) until sacrifice (CL). Group 4: mice from the caloric restricted group.
Mice were fed 60% of food consumed by control mice from the time of weaning until sacrifice
(CR). Mouse chow (Purina 5LG6) containing rapamycin, as well as control chow was prepared at
one site (TestDiet, Richmond, IN) and shipped to each of the three test sites. Detailed description
of diet preparation and interventions is described here [35, 42, 145, 154, 155].
Isolation of Whole cell extract- Whole cell extracts were isolated using hypotonic and hypertonic
salt solutions from transfactor extraction kit (Clontech, Mountain View, CA). Briefly, 100mg of
liver tissue was homogenized with the hypotonic salt solution to lyse the cell and further treated
with the hypertonic salt solution to release the nuclear contents without any fractionations. The
whole cell extract thus obtained was used for various assays.
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Western Blot Analysis- Protein expression analysis was performed using western blot technique as
previously described [76]. 100 g nuclear protein was used to run the SDS-PAGE. Upon
completion of SDS-PAGE, the region containing the proteins of interest was excised and prepared
for western blot analysis while the remaining portion of the gel was stained with Gel Code Blue
Stain Reagent (Pierce Biotechnology, Rockford, IL) to ensure equal protein loading. Manufacturer
recommended dilutions of anti-sera developed against p-AMPK (Abcam), t-AMPK (Millipore),
p-AKT (Cell Signaling), t-AKT (Cell Signaling), REDD1 (Abcam), IPMK (Abcam), p-S6K1 (Cell
Signaling), t-S6K1 (Cell Signaling), p-4EBP1 (Cell Signaling), t-S6K1 (Cell Signaling), PEPCK
(Santa Cruz) and G6PASE (Santa Cruz) were used to detect proteins of interest followed by
incubation with HRP-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz,
CA). The bands were visualized and quantified using a Molecular Imager System (Bio-Rad,
Hercules, CA) after incubation in SuperSignal West Pico Chemiluminescent Substrate (Pierce
Biotechnology, Rockford, IL). Data are expressed as the integrated density value (I.D.V.) of the
band normalized to -actin (Sigma Aldrich) or ratio of phosphorylated form of protein to total
normalized to -actin.
NAD/NADH Assay: Total NAD (NAD and NADH) was extracted from 20 mg of liver using
Abcam’s NAD/NADH Assay kit. This is a calorimetric assay that detects intracellular nucleotides
at OD 570 nm. Total NAD is extracted and detected. Then NAD+ is decomposed to detect NADH.
The values are used to calculate for NAD+. NAD+ levels are expressed as (uM). The ratio of NAD+
to NADH is also calculated.
Statistical Analysis- Statistical significance between means was determined using t-test and
analysis of variance followed by post tukey test wherever appropriate. P-values less than 0.05
were considered statistically significant.
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Results
Analysis of the impact of rapamycin, crowded litter and caloric restriction on animal weight:
Genetically heterogeneous UM-HET3 mice were produced by crossing CByB6F1/J female
mice with C3D2F1/J male mice at the University of Michigan [145, 153]. Animals were divided
into 4 groups: Control, Rapamycin, Crowded Litter and Caloric Restriction. The mice in the
control group were fed a chow diet after they were weaned (CON). The mice in the rapamycin
group were fed a chow diet with encapsulated rapamycin (14 mg/kg food) starting at 6 weeks of
age (RAPA). The mice in the crowded litter group received a transient food restriction during their
first 20 days of life. Litter size was increased by 50% during this period, after which they were fed
a regular chow diet. The mice in the caloric restricted group were fed 60% of food consumed by
control after they were weaned. Animals were sacrificed at various time points for analysis, and
the focus of this study will be on the first group sacrificed at 9 months.
It’s been shown that Rapamycin, crowded litter and caloric restriction extend lifespan in
animal models [5, 6, 42, 147-149, 152]. However, the mechanism behind the longevity seen is still
elusive. We began by looking at the effect of these interventions on body weight at the time of
sacrifice. As shown in Figure 3.1, there was no significant difference in body weight in the
rapamycin or crowded litter group as compared to control. However, we saw a significant decrease
in body weight in the caloric restricted group. Rapamycin, crowded litter and caloric restriction all
increase lifespan in this heterogeneous population of mice, however their impact on the weight of
the animals is not the same.
Analysis of the nutrient sensing pathway - mTOR in the liver of mice on rapamycin, crowded
litter and caloric restriction:
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We looked at the impact of these three interventions on the mTOR pathway. Mammalian
target of rapamycin (mTOR) is a serine/threonine protein kinase that regulates cell growth,
autophagy and proliferation [23]. mTOR signaling is altered in many age related diseases including
cancer [24]. Genetic downregulation of TOR signaling delays aging in evolutionary distant
organisms from yeast to mammals [26]. mTOR exists in two multiprotein complexes: mTORC1
and mTORC2. mTORC1 pathway integrates input from various upstream intracellular and
extracellular signals that include: growth factors (ILGF), stress, hypoxia, energy status
(AMP/ATP, NAD+ /NADH), purine metabolism, and amino acid levels [101]. However, mTORC2
is not sensitive to nutrients but responds to growth factors by poorly defined mechanisms [23].
We collected liver samples from UM-HET3 male mice upon sacrifice at 9 months of age
from the University of Michigan. We looked at the impact of rapamycin, crowded litter and caloric
restriction on various upstream regulators of mTOR, starting with energy metabolism. NAD cycles
between the oxidized (NAD+) and reduced (NADH) forms, partaking a central role in cellular
metabolism and energy production [100]. We saw an increase in NAD+ levels (Figure 3.2), and
NAD+/NADH ratio (Figure 3.3) in all three experimental groups as compared to control. We then
looked at the impact of rapamycin, crowded litter and caloric restriction on IPMK. IPMK mediates
the activation of mTORC1 in response to amino acids and glucose [106, 107]. There was no
significant difference in the expression of IPMK in rapamycin and crowded litter Figure 3.4.
However, we saw a significant increase in expression in the caloric restricted group; possibly a
feedback mechanism due to downregulated mTOR. We looked at REDD1 levels, which increase
following exposure to hypoxia or DNA damage, leading to inhibition of mTOR signaling. There
was no significant difference in expression of REDD1 in the rapamycin group (Figure 3.5) which
is what we expected. However, there was a significant increase in crowded litter and a significant
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decrease in caloric restriction. This suggests that the transient food restriction early on in life in
the crowded litter group is triggering alternate pathways that may be resulting in the extension of
lifespan.
We looked at the phosphorylation of AMPK, a metabolic fuel gauge that detects changes
in intracellular AMP/ATP ratio [108]. AMPK is activated in response to nutrient depletion and
works to maintain energy stores [108]. AMPK directly inhibits mTORC1, and neutralizes PI3K
activation of mTORC1. We saw a significant increase in AMPK phosphorylation in all three
group, with the highest increase in the caloric restricted group (Figure 3.6). Activation of AMPK
in response to low energy inhibits hepatic gluconeogenesis in an insulin independent manner [111].
However, there was no significant difference on the effect of these interventions on PEPCK
expression (rate limiting enzyme in gluconeogenesis) (Figure 3.7). On the contrary, we did see a
significant decrease in G6PASE expression in response to rapamycin only (Figure 3.8). When we
analyzed the effect of rapamycin, crowded litter and caloric restriction on phosphorylation of AKT
S473, which is mTORC2 dependent, we saw a significant increase in expression in the caloric
restricted group only (Figure 3.9).
The final part that we analyzed was the impact of rapamycin, crowded litter and caloric
restriction on protein synthesis. Protein synthesis is the best characterized process downstream of
mTORC1 through phosphorylation of two downstream target proteins: S6K1 and 4E-BP1[23].
There was a significant decrease in phosphorylation of 4EBP1 in the caloric restricted group only
(Figure 3.10). However, we saw a significant decrease in phosphorylation of S6K1 in both
rapamycin and caloric restricted groups (Figure 3.11). This differential effect of rapamycin on
protein synthesis was also shown by Choo et al. [156].
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Rapamycin, crowded litter and caloric restriction have been shown to extend lifespan in
animal models. However, the mechanisms by which they do so are not fully understood. Here we
show that although these three interventions extend lifespan, they have a differential effect on the
mTOR signaling pathway. The mTOR signaling pathway may be one of the mechanisms by which
rapamycin and caloric restriction are working to extend lifespan. However, we speculate that
alternate mechanisms are being activated in the crowded litter group. The transient food restriction
during their first 20 days of life may be resulting in the extension of lifespan irrespective of mTOR.
Discussion
The National Institute on Aging (NIA) developed an Interventions Testing Program (ITP)
to evaluate possible agents that may delay the rates of aging. Researchers speculate that delaying
aging in general could greatly benefit human health as a whole. The beneficial effect could
potentially be greater than any effect seen by targeting individual forms of age related diseases
[145]. They evaluated various candidates every year using genetically heterogeneous mice. Studies
were replicated at three test sites (the Jackson Laboratory (TJL), University of Michigan (UM),
and University of Texas (UT)) and included sufficient statistical power to detect a 10% change in
lifespan [145].
The focus of this research was on a cohort study from UM evaluating the effects of
rapamycin, crowded litter and caloric restriction on aging. It’s been shown that Rapamycin,
crowded litter and caloric restriction extend lifespan in animal models [5, 6, 42, 147-149, 152].
Rapamycin is an immunosuppressant drug that directly inhibits the TOR kinase of mTORC1.
Caloric restriction has also been shown to inhibit mTOR [36]. However data is lacking on the
effect of crowded litter on mTOR, and whether these interventions affect the upstream regulators
of mTOR similarly.
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Animals were divided into 4 groups: Control (Chow diet), Rapamycin (14 mg/kg diet
encapsulated rapamycin), Crowded Litter (transient food restriction during first 20 days of life)
and Caloric Restriction (60% of food consumed by control). At 9 months of age, animals were
sacrificed for analysis. Upon examining their body weights, we did not see any significant
difference in the rapamycin or crowded litter groups as compared to control. However, there was
a significant decrease in body weight in the caloric restricted group as compared to the rest.
Since the focus of our lab is mTOR, we characterized the impact of these life extending
strategies on the mTOR signaling pathway. mTOR is a major nutrient sensing pathway that
impacts aging, and many age-related diseases. Inhibition of mTOR extends life-span in many
laboratory models including yeast, worms, flies and rodents [35, 119, 143, 144]. mTOR is
impacted by changes in NAD+ levels and NAD+/NADH ratio. We showed that there was an
increase in NAD+ levels and NAD+/NADH ratio in all three groups. Rapamycin, crowded litter
and caloric restriction also increased phosphorylation of AMPK, a metabolic fuel gauge that senses
changes in AMP/ATP ratio, and modulates mTORC1. Rapamycin and caloric restriction
downregulate mTORC1 as observed by the decreased activation of two downstream targets: S6K1
and/or 4E-BP. However, we did not see any significant difference on the impact of crowded litter
on mTOR, suggesting that crowded litter may be activating alternate pathways that may be
resulting in the beneficial longevity effect.
Furthermore, caloric restriction significantly increased AKT S473 phosphorylation. This
site is phosphorylated by mTORC2. Caloric restriction increased phosphorylation of AKT at the
S473 residue possibly as a compensatory mechanism to maintain insulin sensitivity [5, 140].
However, we did not see any significant difference on phosphorylation of AKT S473 in the
rapamycin or crowded litter group. Interestingly, there was no significant difference in the
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expression of the gluconeogenesis enzyme PEPCK. However, G6PASE expression was
significantly less in the rapamycin group.
When we analyzed the impact on REDD1 and IMPK we did not see any significant
difference in the rapamycin group. Crowded litter only impacted REDD1 expression, while caloric
restriction significantly impacted both. These data indicate that Rapamycin and caloric restriction
are impacting and downregulating the mTOR signaling pathway, as shown by the decrease in
downstream protein synthesis. The longevity effect may be regulated in part by downregulation of
mTOR, however, they impact upstream regulators of mTOR differently. On the other hand,
crowded litter does not impact the mTOR pathway. We speculate that crowded litter is impacting
alternate pathways early on in life that are resulting in this beneficial longevity effect, irrespective
of mTOR.
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Figure 3.1: Effect of Rapamycin, crowded litter and caloric restriction on weight of heterogeneous
UM-HET3 male mice. Genetically heterogeneous UM-HET3 mice were produced by crossing
CByB6F1/J female mice with C3D2F1/J male mice at three test sites: the Jackson laboratory (TJL),
the University of Michigan (UM), or the University of Texas Health Center at San Antonio (UT)
[145, 153]. Animals were divided into 4 different groups at the University of Michigan. Group 1:
control mice were fed a chow diet (Purina 5LG6) from the time they were weaned until sacrifice
(CON). Group 2: mice were fed encapsulated rapamycin (14 mg/kg food) incorporated into chow
diet (Purina 5LG6) (RAPA) starting at 6 weeks of age. Group 3: mice from a crowded litter. The
size of the litter was increased to 12 pups per nursing mother. After 20 days, pups were weaned
onto a normal chow diet (Purina 5LG6) until sacrifice (CL). Group 4: mice from the caloric
restricted group. Mice were fed 60% of food consumed by control mice from the time of weaning
until sacrifice (CR). The weights of animals were taken upon sacrifice at 9 months of age. Values
represent an average [S.E.M] for data obtained from 8 mice in each group. Different letters
significantly different at P < 0.05. CON: Control Group; RAPA: Rapamycin Group; CL: Crowded
Litter Group; CR: Caloric Restriction Group.
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Figure 3.1: Effect of Rapamycin, crowded litter and caloric restriction on weight of
heterogeneous UM-HET3 male mice.
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Figure 3.2: Effect of Rapamycin, crowded litter and caloric restriction on NAD+ levels. Total NAD
(NAD+ and NADH) was extracted from the liver of heterogeneous UM-HET3 male mice from all
4 experimental groups (CON, RAPA, CL, and CR), using Abcam’s NAD/NADH Assay kit.
Intracellular nucleotides were detected using a plate reader at OD 570 nm. Total NAD is extracted
and detected. Then NAD+ is decomposed to detect NADH. The values are then used to calculate
for NAD+. NAD+ levels are expressed as (uM). Values represent an average [S.E.M] for data
obtained from 4 mice in each group and are representative of separate identical experiments. CON:
Control Group; RAPA: Rapamycin Group; CL: Crowded Litter Group; CR: Caloric Restriction
Group.
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Figure 3.2: Effect of Rapamycin, crowded litter and caloric restriction on NAD+ levels.
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Figure 3.3: Effect of Rapamycin, crowded litter and caloric restriction on NAD+/NADH ratio.
Total NAD (NAD+ and NADH) was extracted from the liver of heterogeneous UM-HET3 male
mice from all 4 experimental groups (CON, RAPA, CL, and CR), using Abcam’s NAD/NADH
Assay kit. Intracellular nucleotides were detected using a plate reader at OD 570 nm. First, total
NAD is extracted and detected. Then NAD+ is decomposed to detect NADH. The values are then
used to calculate for NAD+. NAD+/NADH ratio calculated. Values represent an average [S.E.M]
for data obtained from 4 mice in each group and are representative of separate identical
experiments. CON: Control Group; RAPA: Rapamycin Group; CL: Crowded Litter Group; CR:
Caloric Restriction Group.
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Figure 3.3: Effect of Rapamycin, crowded litter and caloric restriction on NAD+/NADH ratio.
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Figure 3.4: Effect of Rapamycin, crowded litter and caloric restriction on expression of IPMK
protein. The level of IPMK protein in 100 ug of liver whole cell extract from heterogeneous
UM-HET3 male mice from all 4 experimental groups (CON, RAPA, CL, and CR) was
determined by western blot analysis. The level of IPMK was normalized based on the amount of
protein loaded. The I.D.V (integrated density value) corresponding to the level of IPMK protein
as quantified by the BioRad Molecular Imager® System, normalized to β-actin. Values represent
an average [S.E.M] for data obtained from 3 mice in each group and are representative of
separate identical experiments. Different letters significantly different at P < 0.05. CON: Control
Group; RAPA: Rapamycin Group; CL: Crowded Litter Group; CR: Caloric Restriction Group.
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Figure 3.4: Effect of Rapamycin, crowded litter and caloric restriction on expression of IPMK
protein.

47 KDa
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Figure 3.5: Effect of Rapamycin, crowded litter and caloric restriction on expression of REDD1
protein. The level of REDD1 protein in 100 ug of liver whole cell extract from heterogeneous UMHET3 male mice from all 4 experimental groups (CON, RAPA, CL, and CR) was determined by
western blot analysis. The level of REDD1 was normalized based on the amount of protein loaded.
The I.D.V (integrated density value) corresponding to the level of REDD1 protein as quantified
by the BioRad Molecular Imager® System, normalized to β-actin. Values represent an average
[S.E.M] for data obtained from 3 mice in each group and are representative of separate identical
experiments. Different letters significantly different at P < 0.05. CON: Control Group; RAPA:
Rapamycin Group; CL: Crowded Litter Group; CR: Caloric Restriction Group.
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Figure 3.5: Effect of Rapamycin, crowded litter and caloric restriction on expression of REDD1
protein.

25 KDa
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Figure 3.6: Effect of Rapamycin, crowded litter and caloric restriction on AMPK phosphorylation.
The level of AMPK protein in 100 ug of liver whole cell extract from heterogeneous UM-HET3
male mice from all 4 experimental groups (CON, RAPA, CL, and CR) was determined by western
blot analysis. The level of the phosphorylated form of AMPK was determined first. The membrane
was then stripped and tested for Total AMPK. The I.D.V (integrated density value) corresponding
to the level of AMPK protein (phosphorylated and total) was quantified by the BioRad Molecular
Imager® System. Phosphorylated AMPK was normalized to total and expressed as p-AMPK
protein expression ratio. Values represent an average [S.E.M] for data obtained from 3 mice in
each group and are representative of separate identical experiments. Different letters significantly
different at P < 0.05. CON: Control Group; RAPA: Rapamycin Group; CL: Crowded Litter Group;
CR: Caloric Restriction Group.
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Figure 3.6: Effect of Rapamycin, crowded litter and caloric restriction on AMPK
phosphorylation.

62 KDa
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Figure 3.7: Effect of Rapamycin, crowded litter and caloric restriction on gluconeogenesis enzyme
PEPCK. The levels of PEPCK protein in 100 ug of liver whole cell extract from heterogeneous
UM-HET3 male mice from all 4 experimental groups (CON, RAPA, CL, and CR) were determined
by western blot analysis. The level of PEPCK was normalized based on the amount of protein
loaded. The I.D.V (integrated density value) corresponding to the level of PEPCK protein as
quantified by the BioRad Molecular Imager® System, normalized to β-actin. Values represent an
average [S.E.M] for data obtained from 3 mice in each group and are representative of separate
identical experiments. Different letters significantly different at P < 0.05. CON: Control Group;
RAPA: Rapamycin Group; CL: Crowded Litter Group; CR: Caloric Restriction Group.
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Figure 3.7: Effect of Rapamycin, crowded litter and caloric restriction on gluconeogenesis
enzyme PEPCK.

62 KDa
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Figure 3.8: Effect of Rapamycin, crowded litter and caloric restriction on gluconeogenesis enzyme
G6PASE. The levels of G6PASE protein in 100 ug of liver whole cell extract from heterogeneous
UM-HET3 male mice from all 4 experimental groups (CON, RAPA, CL, and CR) were determined
by western blot analysis. The level of G6PASE was normalized based on the amount of protein
loaded. The I.D.V (integrated density value) corresponding to the level of G6PASE protein as
quantified by the BioRad Molecular Imager® System, normalized to β-actin. Values represent an
average [S.E.M] for data obtained from 3 mice in each group and are representative of separate
identical experiments. Different letters significantly different at P < 0.05. CON: Control Group;
RAPA: Rapamycin Group; CL: Crowded Litter Group; CR: Caloric Restriction Group.

109

Figure 3.8: Effect of Rapamycin, crowded litter and caloric restriction on gluconeogenesis
enzyme G6PASE.

36 KDa
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Figure 3.9: Effect of Rapamycin, crowded litter and caloric restriction on AKT SER473
phosphorylation. The level of AKT protein in 100 ug of liver whole cell extract from
heterogeneous UM-HET3 male mice from all 4 experimental groups (CON, RAPA, CL, and CR)
was determined by western blot analysis. The level of the phosphorylated form of AKT at SER473
residue was determined first. The membrane was then stripped and tested for Total AKT. The
I.D.V (integrated density value) corresponding to the level of AKT protein (phosphorylated and
total) was quantified by the BioRad Molecular Imager® System. P-AKT (ser473) was normalized
to total AKT and expressed as p-AKT ser473 protein expression ratio. Values represent an average
[S.E.M] for data obtained from 3 mice in each group and are representative of separate identical
experiments. Different letters significantly different at P < 0.05. CON: Control Group; RAPA:
Rapamycin Group; CL: Crowded Litter Group; CR: Caloric Restriction Group.
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Figure 3.9: Effect of Rapamycin, crowded litter and caloric restriction on AKT SER473
phosphorylation.

60 KDa
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Figure 3.10: Effect of Rapamycin, crowded litter and caloric restriction on 4EBP-1
phosphorylation. The level of 4EBP-1 protein in 100 ug of liver whole cell extract from
heterogeneous UM-HET3 male mice from all 4 experimental groups (CON, RAPA, CL, and CR)
was determined by western blot analysis. The level of the phosphorylated form of 4EBP-1 was
determined first. The membrane was then stripped and tested for Total 4EBP-1. The I.D.V
(integrated density value) corresponding to the level of 4EBP-1 protein (phosphorylated and total)
was quantified by the BioRad Molecular Imager® System. Phosphorylated 4EBP-1 was
normalized to total and expressed as p-4EBP-1 protein expression ratio. Values represent an
average [S.E.M] for data obtained from 3 mice in each group and are representative of separate
identical experiments. Different letters significantly different at P < 0.05. CON: Control Group;
RAPA: Rapamycin Group; CL: Crowded Litter Group; CR: Caloric Restriction Group.
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Figure 3.10: Effect of Rapamycin, crowded litter and caloric restriction on 4EBP-1
phosphorylation.

20 KDa
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Figure 3.11: Effect of Rapamycin, crowded litter and caloric restriction on S6K1 phosphorylation.
The level of S6K1 protein in 100 ug of liver whole cell extract from heterogeneous UM-HET3
male mice from all 4 experimental groups (CON, RAPA, CL, and CR) was determined by western
blot analysis. The level of the phosphorylated form of S6K1 was determined first. The membrane
was then stripped and tested for Total S6K1. The I.D.V (integrated density value) corresponding
to the level of S6K1 protein (phosphorylated and total) was quantified by the BioRad Molecular
Imager® System. Phosphorylated S6K1 was normalized to total and expressed as p-S6K1 protein
expression ratio. Values represent an average [S.E.M] for data obtained from 3 mice in each group
and are representative of separate identical experiments. Different letters significantly different at
P < 0.05. CON: Control Group; RAPA: Rapamycin Group; CL: Crowded Litter Group; CR:
Caloric Restriction Group.
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Figure 3.11: Effect of Rapamycin, crowded litter and caloric restriction on S6K1
phosphorylation.

70 KDa
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS
Aging is a multifactorial process that is implicated with alterations in several physiological
functions, such as loss of homeostasis and loss of functional capacity [1]. It is associated with
many diseases including cardiovascular disease, cancer and type II diabetes mellitus [5]. Since
these diseases are highly prevalent in the aging population, targeting the aging process as a whole
may delay the occurrence of these age related disease, in turn delaying aging. Various interventions
have been shown to delay aging including: caloric restriction [6], methionine restriction [9],
genetic alterations such as Ames dwarf mice [13], rapamycin [35], and metformin [19]. These
interventions inhibit a major nutrient sensing pathway, mammalian target of rapamycin (mTOR),
a pathway shown to be altered in many cancers [26, 35-39]. Down-regulation of this pathway also
delays aging in a number of organisms, ranging from yeast to mammals [27, 28, 38, 40-42].
Alterations in one carbon metabolism, a major pathway upstream of mTOR, also extends lifespan
in animal models [70, 71]. Metformin, an emerging gerosuppresant, impairs one carbon
metabolism in a manner similar to anti-folate drugs [21]. We have previously shown that folate
restriction decreased markers of proliferation such as mTOR in our β-pol haploinsufficient
background [31]. In this study, we present folate restriction as a possible nutritional intervention
to extend lifespan and improve health span in our animal model, modulating the one carbon
metabolism and the mTOR signaling pathway.
We established an animal model to study the impact of folate status in the diet on plasma
folate levels. We showed that by feeding the animals a folate depleted diet (0 mg folic acid per kg
of diet), their plasma folate levels dropped by the third day on the diet, and plateaued at a 90%
decrease for the duration of the study. Since we did not observe any further decrease in plasma
folate, and the animals did not show any signs of anemia, we termed this condition folate restriction
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(FR) rather than folate deficiency. Low folate status has been associated with the development and
progression of various types of cancer, however, some studies show that low folate may be
protective against cancer [52-54, 77-79]. Inconsistencies in these studies may be due to differences
in experimental design, dosages, timing and duration of folate deficiency. We showed that folate
restriction did not result in the development of spontaneous preneoplastic lesions. However, when
exposed to a carcinogen, the timing and duration of folate restriction had a differential effect on
the development of ACF. When we placed the animals on one week of folate restriction before
exposing them to a carcinogen, we saw a significant increase in preneoplastic lesions. However,
when the animals were given time to adapt to folate restriction before we exposed them to a
carcinogen, we saw significantly less ACF. We showed that folate restriction by itself is a low
penetrance event and does not independently give rise to spontaneous preneoplastic legions. We
also showed that the timing and duration of folate restriction before exposure to a carcinogen
resulted in a differential effect on ACF formation. Future studies will focus on understanding the
mechanism behind the differential effect seen due to timing and duration of folate restriction.
Folate restriction altered the one carbon metabolism and the mTOR signaling pathway,
shedding light on the anti-proliferative and anti-cancer effects observed. We showed that folate
restriction resulted in a decrease in branched chain amino acids that have regulatory effects on
cellular proliferation and growth. Folate restriction also decreased ATP levels directly impacting
energy metabolism, and activating AMPK. AMPK, a direct inhibitor of mTORC1, enhanced
SIRT1 activity by increasing cellular levels of NAD+, decreasing proliferation. Folate restriction
downregulated the mTOR signaling pathway decreasing protein synthesis, as shown by the
decrease in p-S6K1 and p-4ebp1. Furthermore, folate restriction reduced apoptotic activity,
possibly slowing down the aging process as a result of modulation between reduced damage and
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reduced proliferation. Folate restriction also increased median lifespan in our aging colony. In this
study, we have identified a direct link between the folate cycle and the nutrient sensing mTOR
pathway that converge on target genes, mainly activation of AMPK, impacting aging and cancer.

As a comparative analysis, we studied the impact of three known life extending strategies
on the mTOR signaling pathway. We were given access to samples from a longevity study done
at the University of Michigan as part of an Interventions testing program. The interventions
included Rapamycin, crowded litter and caloric restriction which have all been shown to extend
lifespan [5, 6, 42, 147-149, 152]. We showed that at 9 months of age, rapamycin and caloric
restriction decreased expression of downstream targets of mTOR similar to folate restriction.
However, when we analyzed the upstream regulators of mTOR, we saw a differential impact.
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Although rapamycin, caloric restriction and folate restriction downregulated mTOR, the means by
which they did differed. Crowded litter on the other hand did not impact the mTOR signaling
pathway. We speculate that the transient food restriction early on in life triggered alternate
pathways that provided this beneficial long lasting anti-aging effect irrespective of mTOR.
Future studies will include investigating the protective mechanism behind the longevity
effect seen in the crowded litter group. We propose that the period of stress imposed by the
transient food restriction early on in life may result in epigenetic changes that render these animals
less susceptible to aging. It may also converge on the concept of mitohormesis, a response to mild
mitochondrial stress that renders the cell less susceptible to subsequent perturbations, impacting
susceptibility to disease and aging.
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ABSTRACT
THE IMPACT OF FOLATE RESTRICTION ON CANCER AND AGING: A
MECHANISTIC ANALYSIS
by
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Aging is a multifactorial process associated with alterations in several physiological
functions. It increases susceptibility to disease and ultimately results in mortality. Since the
associated diseases of aging are highly prevalent in the geriatric population, targeting the aging
process as a whole may provide a better way to delay these age related diseases, in turn delaying
aging. Various interventions have been shown to delay aging and age related diseases. They impact
a major nutrient sensing pathway, mTOR. mTOR signaling is altered in many cancers and its
downregulation was shown to delay aging. Other interventions extend lifespan by altering the one
carbon metabolism. In this study, we present folate restriction as a possible nutritional intervention
to extend lifespan and improve health span impacting one carbon metabolism and the mTOR
signaling pathway.
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